WO2007017892A2 - Novel compounds as glp-i agonists - Google Patents

Novel compounds as glp-i agonists Download PDF

Info

Publication number
WO2007017892A2
WO2007017892A2 PCT/IN2006/000154 IN2006000154W WO2007017892A2 WO 2007017892 A2 WO2007017892 A2 WO 2007017892A2 IN 2006000154 W IN2006000154 W IN 2006000154W WO 2007017892 A2 WO2007017892 A2 WO 2007017892A2
Authority
WO
WIPO (PCT)
Prior art keywords
bip
ome
pyr
ala
aib
Prior art date
Application number
PCT/IN2006/000154
Other languages
French (fr)
Other versions
WO2007017892A3 (en
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Rajesh H. Bahekar
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007013655A priority Critical patent/MX2007013655A/en
Priority to JP2008509578A priority patent/JP2008540402A/en
Priority to AU2006277557A priority patent/AU2006277557A1/en
Priority to EA200702419A priority patent/EA200702419A1/en
Priority to AP2007004227A priority patent/AP2007004227A0/en
Priority to CA002606894A priority patent/CA2606894A1/en
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Priority to BRPI0612471A priority patent/BRPI0612471A2/en
Priority to EP06809915A priority patent/EP1891106A2/en
Publication of WO2007017892A2 publication Critical patent/WO2007017892A2/en
Publication of WO2007017892A3 publication Critical patent/WO2007017892A3/en
Priority to IL187105A priority patent/IL187105A0/en
Priority to NO20075618A priority patent/NO20075618L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel compounds of general formula (I), their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
  • the present invention relates to novel Glucagon-Like Peptide- 1 (GLP-I) peptide mimics (peptidomimetic), which act as GLP-I receptor agonists and exhibit most of the biological activity of the native GLP-I.
  • GLP-I peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme and can be delivered by both invasive and various non-invasive routes of administrations such as oral, nasal, buccal, pulmonary and transdermal route of administration, for the treatment or prevention of diabetes and related conditions.
  • the present invention also relates to a process of preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
  • the GLP-I (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.
  • the physiological action of GLP-I has gained considerable interest. GLP-I exerts multiple action by stimulating insulin secretion from pancreatic ⁇ -cells, in a glucose dependent manner (insulinotropic action). GLP-I also lowers circulating plasma glucagon concentration, by inhibiting its secretion from ⁇ -cells (Drucker D. J., Endocrinology, 142, 521-527, 2001). More recently, it has become clear that GLP-I also exhibits properties like stimulation of ⁇ -cell growth, appetite suppression, delayed gastric emptying and stimulation of insulin sensitivity (Nauck, Horm. Metab. Res., 47, 1253-1258, 1997).
  • the venom of the GiIa Monster Heloderma Suspectuni contains a 39 amino acid peptide called Exendin-»4 (EX-4) that shares around 50 % sequence identity to GLP-I itself, exhibits a very potent GLP-IR (Glucagon like peptide-1 receptor) agonist activity (Thorens B., Diabetes, 42, 1678 - 1682, 1993). Indeed, it was found that EX-4 is much more potent than native GLP-I peptide, because of its relatively longer half- life (25 min., iv route of administration), compared to GLP-I (2-5 min., iv route of administration).
  • EX-4 Glucagon like peptide-1 receptor
  • Exendin-4 binds with greater affinity to the GLP-IR, due to presence of the nine extra C-terminal sequence (Doyle M.E., Regulatory Peptides, 114, 153-158, 2003).
  • Doyle M.E. Regulatory Peptides, 114, 153-158, 2003.
  • Native or synthetic GLP-I peptide is rapidly metabolized by the proteolytic enzymes, such as dipeptidyl peptidase-IV (DPP-IV) into an inactive metabolite, thereby limiting the use of GLP-I as a drug.
  • DPP-IV dipeptidyl peptidase-IV
  • GLP-I and EX-4 are in different stages of clinical development (Nauck M. A., Regulatory Peptides, 115, 13-19, 2004).
  • the GLP-I R is a seven-transmembrane domain G-protein-coupled receptor (GPCR) and it is located on the cell membrane of pancreatic ⁇ -cells.
  • the effector system of GLP-I R is the Adenylyl Cyclase (AC) enzyme. Interaction of GLP-I agonist with GLP-IR causes activation of AC, which converts ATP to cAMP. Increase in the intracellular cAMP level raises the ratio of ADP/ATP, thereby initiating the cell depolarization (due to closure of K ATP channel).
  • PK-A & PK-C Protein Kinase
  • cystolic Ca 2+ concentration by opening of L-type of Ca 2+ channel.
  • An increase in the intracellular Ca 2+ leads to exocytosis of insulin, in pancreatic ⁇ -cells (Fehmann, H.C., Endocr. Rev., 16, 390 - 410, 1995).
  • peptidomimetics which act as a GLP-IR agonist and exhibit most of the biological activity of the native GLP-I peptide. Furthermore, these GLP-I peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV enzyme and therefore, surprisingly found to have an increased half-life making them suitable for the treatment / mitigation / prophylaxis of both type 1 & type 2 diabetes, metabolic disorders, obesity and related disorders. Summary of the invention
  • the present invention describes a group of novel peptidomimetics useful for the treatment of diabetes. These compounds are defined by the general formula (I) as given below.
  • the compounds of the present invention are useful in the treatment of the human or animal body, by regulation of insulin secretion. The compounds of this invention are therefore suitable for the treatment/mitigation/regulation or prophylaxis of both type 1 & type 2 diabetes and obesity.
  • the main object of the present invention is to provide novel compounds of general formula (I), their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures, suitable for the treatment treatment/mitigation/regulation of diabetes.
  • compositions containing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, solvates and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture are provided.
  • Aib ⁇ -Aminoisobutyric acid
  • ACN or MeCN Acetonitrile
  • Bip Biphenylalanine residue
  • Bip(2-CN) 2-nitrile biphenyl residue
  • Bip(2-Ipr) 2-Isopropyl biphenyl residue
  • DIPCDI Di-isopropylcarbodiimide
  • DIPEA Diisopropylethylamine
  • Et Ethyl
  • Et 2 O Diethyl ether
  • Fmoc Fluorenylmethoxycarbonyl
  • HOAT 7-Aza-hydroxybenzotriazole
  • HBTU 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyl aminium hexafluorophosphate
  • PyBOP Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
  • TrPh 4-phenyl-biphenylalanine residue
  • TIPS Triisopropylsilane
  • TFA frifluoroacetic acid
  • TBTU 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethylaminium tetrafluoroborate
  • Trt Trityl group
  • synthetic GLP-I analog peptides / peptidomimetics which have the structural formula (I), wherein, A represents -NH-R 1 , wherein R 1 represents hydrogen, groups selected from linear or branched (C 1 -C 15 ) alkyl chain, such as methyl, ethyl, propyl, isopropyl, n-butyl, iso- butyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, decyl groups and the like, an amino acid or peptide containing one, two or three natural amino acid residues, R 3 -CO- group, such as (2-Hydroxy-phenyl)-acetyl group and the like, R 3 O-C(O)- group, such as Fmoc group and the like, a sulfonyl group of formula R 3 -SO 2 -,
  • R 4 represents H, optionally substituted groups selected from linear or branched (Ci-C 10 ) alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, isorbutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, decyl groups and the like, aryl groups selected from phenyl, napthyl, indanyl, fluorenyl, biphenyl and the like; with the proviso that i) when S 1 -Y-S 2 represents a bond, X 1
  • HAEGTFTSDVSS (Seq ID 6), HAEGTFTSDVSSY (Seq ID 7), HAEGTFTSDVSSYL (Seq DD 8), HAEGTFTSDVS SYLE (Seq ID 9),
  • HAEGTFTSDVSSYLEG (Seq ID 10), HAEGTFTSDVS SYLEGQ (Seq ID 11),
  • HAEGTFTSDVSSYLEGQA (Seq JD 12), HAEGTFTSDVS SYLEGQAA (Seq ID 13), HAEGTFTSDVSSYLEGQAAK (Seq TD 14), HAEGTFTSDVS S YLEGQAAKE (Seq ID 15), HAEGTFTSDVSSYLEGQAAKEF (Seq ID 16),
  • HAEGTFTSDVSSYLEGQAAKEFI (Seq ID 17), with the further option that one or more of these amino acids may be replaced by unnatural amino acids, and X 2 is selected from the following amino acid sequences GPSSGAPPPS (Seq ID 18)or KELEKLL (Seq ID 19)or GPPS or (Seq ID 20) VKGR (Seq ID 21); ii) and when SpY-S 2 does not represent a bond X 1 is selected from the following amino acid sequences
  • HA (Seq ID 22), HAE (Seq ID 23), HAEG (Seq ID 24), HAEGT (Seq ID 25), HAEGTF (Seq ID 26), HAEGTFT (Seq ID 27), HAEGTFTS (Seq ID 28), HAEGTFTSD (Seq ID 29) with the further option that one or more of these amino acids may be replaced by unnatural amino acids;
  • X 2 is selected from GPSSGAPPPS (Seq ID 18) or KELEKLL (Seq ID 19)or GPPS (Seq ID 20)or VKGR (Seq ID 21)or a dipeptide, selected from combination of two amino acids, consisting of natural or unnatural amino acids, having a side chain containing an arylalkyl or heteroarylalkyl moieties selected from benzyl, napthylmethyl, pyridylmethyl, thienylmethyl, furylmethyl, imidazolylmethyl, isooxazo
  • the dipeptide sequence may comprise of one or more amino acids selected from Bip, Bip(2-Me), Bip(2-Et), Bip(2-Ipr), Bip(2-CN), Bip(2'-Et-4'-OMe), B ip(4' -fluoro), Bip(4'-Phenyl), 2-(9,10-Dihydro-phenanthrenyl]- Ala, 2-(Phenanthrenyl)-Ala, 4-(2-Naphthyl)-Phe, 4-(l-Naphthyl)-Phe, 2-Fluorenyl-Ala, 4-dibenzofuran-Phe, 4-dibenzothiophene-Phe, 4-(2 ' -methylphenyl)-3 -pyridylalanine;
  • the term 'natural amino acids' indicates all those twenty amino acids, which are present in nature.
  • 'unnatural amino acids' or 'non-natural amino acids' represents either replacement of L-amino acids with corresponding D-amino acids such as replacement of L-AIa with D-AIa or L-Pro with D-Pro and the like or suitable modifications of the L or D amino acids, amino alkyl acids, either by
  • Such 'unnatural amino acids' or 'non-natural amino acids' may be represented generally by the following structure:
  • R 5 wherein Rs is selected from H, F, (C 1 -Cs) alkyl, the stereochemical configuration at the carbon bearing R 5 may be (R) or (S); R 6 is selected from H or (C 1 -C 3 ) alkyl; each of R 7 and R 8 is independently selected from H, (C 1 -C 3 ) alkyl, such as methyl and ethyl or halogen atom, preferably fluorine atom; R 9 represents groups, selected from (C 1 -Cs) alkyl, aryl or heteroryl moieties selected from phenyl, napthyl, pyridyl, thienyl, furyl, imidazolyl, isooxazolyl, quinolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, dibenzofuranyl, dibenzothienyl, benzodihydrofuranyl, benzodihydrothienyl, thien
  • the suitable substituents include, but are not limited to the following radicals, alone or in combination with other radicals - hydroxyl, oxo, halo, thio, nitro, amino, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, carboxylic acid and its derivatives such as esters and amides;
  • alkyl used herein, either alone or in combination with other radicals, denotes a linear or branched radical containing one to ten carbons, such as methyl, ethyl, n-propyl, iy ⁇ -propyl, «-butyl, sec-butyl, tert-butyl, amyl, ?-amyi, «-pentyl, n- hexyl, wo-hexyl, heptyl, octyl, decyl and the like.
  • cycloalkyl used herein, either alone or in combination with other radicals, denotes a radical containing three to seven carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • aryl or "aromatic” used herein, either alone or in combination with other radicals, denotes an aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, such as phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like.
  • arylalkyl denotes an alkyl group, as defined above, attached to an aryl, such as benzyl, phenylethyl, naphthylmethyl, and the like.
  • aryloxy denotes an aryl radical, as defined above, attached to an alkoxy group, such as phenoxy, naphthyloxy and the like, which may be substituted.
  • aralkoxy denotes an arylalkyl moiety, as defined above, such as benzyloxy, phenethyloxy, naphthylmethyloxy, phenylpropyloxy, and the like, which may be substituted.
  • heteroaryl or “heteroaromatic” used herein, either alone or in combination with other radicals, denotes an aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused containing one or more hetero atoms selected from O, N or S, such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidinyl, pyr
  • heteroaryl used herein, either alone or in combination with other radicals, denotes a heteroaryl group, as defined above, attached to a straight or branched saturated carbon chain containing 1 to 6 carbons, such as (2-furyl)methyl, (3- furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1 -methyl- 1 -(2- pyrimidyl)ethyl and the like.
  • heteroaryloxy denotes heteroaryl, heteroarylalkyl, groups respectively, as defined above, attached to an oxygen atom.
  • acyl used herein, either alone or in combination with other radicals, denotes a radical containing one to eight carbons such as formyl, acetyl, propanoyl, butanoyl, wo-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like, which may be substituted.
  • carboxylic acid used herein, alone or in combination with other radicals, denotes a -COOH group, and includes derivatives of carboxylic acid such as esters and amides.
  • ester used herein, alone or in combination with other radicals, denotes -COO- group, and includes carboxylic acid derivatives, where the ester moieties are alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, and the like, which may be substituted.
  • the term 'amino acid' as employed herein alone or as part of another group includes, without limitation, an amino group and a carboxyl group linked to the same carbon, referred to as ' ⁇ ' carbon.
  • the absolute 'S' configuration at the ' ⁇ ' carbon is commonly referred to as the 'L' or natural configuration.
  • the 'R' configuration at the ' ⁇ ' carbon is commonly referred to as the 'D' amino acid.
  • the amino acids are GIy or ⁇ ib and are not chiral.
  • 'receptor modulator' refers to a compound that acts at the GLP-I receptor to alter its ability to regulate downstream signaling events.
  • Example of receptor modulators includes agonist, partial agonist, inverse agonist, allosteric potentiators.
  • the isolated peptidomimetics are a 3-30 mer and such peptide bind to and activates the GLP-I receptor.
  • the synthetic isolated peptidomimetics described herein possess the ability to mimic the biological activity of GLP-I peptide, with preference for agonist activity at GLP-IR.
  • These synthetic peptidomimetics GLP- 1 mimetic exhibit desirable in-vivo properties, thus making them ideal therapeutic candidates for oral or parenteral administration.
  • the present invention provides for compounds of formula (I) pharmaceutical compositions employing such compounds either alone or in combination and for methods of using such compounds.
  • the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), alone or in combination(s), with a pharmaceutically acceptable carrier.
  • a method for treating or delaying the progression or onset of diabetes especially type II diabetes, including complications of diabetes, including retinopathy, neuropathy, nephropathy and delayed wound healing and related diseases such as insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, hyperlipidemia including hypertriglyceridemia, syndrome X, atherosclerosis and hypertension, wherein a therapeutically effective amount of a compound of formula (I) or their combination(s) are administered to a mammal, example, human, a patient in need of treatment.
  • Several synthetic routes can be employed to prepare the compounds of the present invention well known to one skilled in the art of peptide synthesis.
  • the compounds of formula (I), where all symbols are as defined earlier can be synthesized using the methods described below, together with conventional techniques known to those skilled in the art of peptide synthesis, or variations thereon as appreciated by those skilled in the art. Referred methods include, but not limited to those described below.
  • the peptidomimetics thereof described herein may be produced by chemical synthesis using suitable variations of various solid-phase techniques generally known such as those described in G. Barany & R. B. Merrifield, "The peptides: Analysis, synthesis, Biology”; Volume 2- “Special methods in peptide synthesis, Part A", pp. 3- 284, E. Gross & J. Meienhofer, Eds., Academic Press, New York, 1980; and in J. M. Stewart and J. D. Young, "Solid-phase peptide synthesis” 2nd Ed., Pierce chemical Co., Rockford, II, 1984.
  • the preferred strategy for preparing the peptidomimetics of this invention is based on the use of Fmoc-based SPPS approach, wherein Fmoc (9-Fluorenyl-methyl- methyloxycarbonyl) group is used for temporary protection of the ⁇ -amino group, in combination with the acid labile protecting groups, such as t-butyloxy carbonyl (Boc), tert-butyl (Bu 4 ), Trityl (Trt) group for temporary protection of the amino acid side chains (see for example E. Atherton & R.C.
  • the peptidomimetics can be synthesized in a stepwise manner on an insoluble polymer support (resin), starting form the C-terminus of the peptide.
  • the synthesis is initiated by appending the C-terminal amino acid of the peptide to the resin through formation of an amide, ester or ether linkage. This allows the eventual release of the resulting peptide as a C-terminal amide, carboxylic acid or alcohol, respectively.
  • the C-terminal amino acid and all other amino acids used in the synthesis are required to have their ⁇ -amino groups and side chain functionalities (if present) differentially protected (orthogonal protection), such that the ⁇ -amino protecting group may be selectively removed during the synthesis, using suitable base such as 20% piperidine solution, without any premature cleavage of peptide from resin or deprotection of side chain protecting groups, usually protected with the acid labile protecting groups.
  • suitable base such as 20% piperidine solution
  • the coupling of an amino acid is performed by activation of its carboxyl group as an active ester and reaction thereof with unblocked ⁇ -amino group of the N-terminal amino acid appended to the resin.
  • peptidyl-resin was washed with the excess of solvents, such as DMF, DCM and diethyl ether.
  • solvents such as DMF, DCM and diethyl ether.
  • the sequence of ⁇ -amino group deprotection and coupling is repeated until the desired peptide sequence is assembled.
  • the peptide is then cleaved from the resin with concomitant deprotection of the side chain functionalities, using an appropriate cleavage mixture, usually in the presence of appropriate scavengers to limit side reactions.
  • the resulting peptide is finally purified by reverse phase HPLC.
  • the synthesis of the peptidyl-resins required as precursors to the final peptides utilizes commercially available cross-linked polystyrene polymer resins (Novabiochem, San Diego, CA).
  • Preferred for use in this invention are Fmoc-PAL-PEG-PS resin, 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-/7-methyl benzhydrylamine resin (Fmoc-Rink amide MBHA resin), 2-chloro-Trityl-chloride resin or p- benzyloxybenzyl alcohol resin (HMP resin) to which the C-terminal amino acid may or may not be already attached.
  • Fmoc-PAL-PEG-PS resin 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-/7-methyl benzhydrylamine resin
  • the C-terminal amino acid is not attached, its attachment may be achieved by HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI.
  • HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI.
  • 2-Chloro-trityl resin coupling of first Fmoc-protected amino acid was achieved, using DIPEA.
  • N- terminal protection of peptidyl resin was selectively deprotected using a solution of 10- 20 % piperidine solution. After every coupling and deprotection, excess of amino acids and coupling reagents was removed by washed with a DMF, DCM and ether.
  • Coupling of the subsequent amino acids can be accomplished using HOBt or HOAT active esters produced from DIPCDI/ HOBt or DIPCDI/HOAT, respectively.
  • HOBt or HOAT active esters produced from DIPCDI/ HOBt or DIPCDI/HOAT, respectively.
  • complete coupling can be achieved using a combination of highly efficient coupling agents such as HBTU, PyBOP or TBTU, with additives such as DIPEA.
  • Peptide + Resin The synthesis of the peptide analogs described herein can be carried out by using batchwise or continuos flow peptide synthesis apparatus.
  • the non-natural noncommercial amino acids present at different position were incorporated into the peptide chain, using one or more methods known in the art.
  • a Fmoc-protected non-natural amino acid was prepared in solution, using appropriate literature procedures.
  • the Fmoc-protected Bip analogs, described above were prepared using modified Suzuki cross coupling method, as known in literature (for e.g. Tetrahedron Letter 58, 9633-9695, 2002).
  • the Fmoc-protected ⁇ -methylated amino acids were prepared using asymmetric Strecker synthesis, as described for e.g. in Org. Letters 3(8), 1121-1124, 2001.
  • the Fmoc-protected N-methylated amino acids were prepared using a literature method as described in for e.g. JOC, 2005, 70, 6918-6920.
  • the resulting derivative was then used in the step-wise synthesis of the peptide.
  • the required non-natural amino acid was built on the resin directly using synthetic organic chemistry procedures and a linear peptide chain were build.
  • the peptide-resin precursors for their respective peptidomimetics may be cleaved and deprotected using suitable variations of any of the standard cleavage procedures described in the literature (see, for example, D. S. King et al. Int. J. peptide Protein res. 36, 1990, 255 - 266).
  • a preferred method for use in this invention is the use of TFA cleavage mixture, in the presence of water and TIPS as scavengers.
  • the peptidyl-resin was incubated in TFA / Water /TIPS (94:3:3; V: V: V; 10 ml / 100 mg of peptidyl resin) for 1.5-2 hrs at room temperature.
  • the cleaved resin is then filtered off, the TFA solution is concentrated or dried under reduced pressure.
  • the resulting crude peptide is either precipitated or washed with Et 2 O or is re-dissolved directly into DMF or 50 % aqueous acetic acid for purification by preparative HPLC. Peptidomimetics with the desired purity can be obtained by purification using preparative HPLC.
  • the solution of crude peptide is injected into a semi-Prep column (Luna lO ⁇ ; C 18 ; 100 A ° ), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 ml /min with effluent monitoring by PDA detector at 220 nm.
  • the structures of the purified peptidomimetics can be confirmed by Electrospray Mass Spectroscopy (ES-MS) analysis.
  • peptide prepared were isolated as trifluoro-acetate salt, with TFA as a counter ion, after the Prep-HPLC purification.
  • some peptides were subjected for desalting, by passing through a suitable ion exchange resin bed, preferably through anion-exchange resin Dowex SBR P(Cl) or an equivalent basic anion-exchange resin.
  • TFA counter ions were replaced with acetate ions, by passing through suitable ion-exchange resin, eluted with dilute acetic acid solution.
  • selected peptides, with the acetate salt was treated with 4 M HCl. The resulting solution was filtered through a membrane filter (0.2 ⁇ m) and subsequently
  • the present invention provides a method of making a peptidomimetics that mimics the activity of an endogenous polypeptide GLP-IR agonist.
  • the polypeptide receptor agonist is GLP-I.
  • novel compounds of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients as are well known.
  • the pharmaceutical composition is provided by employing conventional techniques.
  • the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula (I) either alone or combination, according to this invention.
  • the quantity of active component, that is, the compounds of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration.
  • the daily oral dosage of the active ingredient when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day and most preferably between about 0.6 to 20 mg/kg/day.
  • Washed resin was incubated in freshly distilled DMF (1 ml / 100 mg of resin), under nitrogen atmosphere for 5 minutes.
  • a 0.5 M solution of first Fmoc- protected amino acid (1-3 eq.), pre-activated with HOBt (1-3 eq.) and DIPCDI (1-2 eq.) in DMF was added to the resin, and the resin was then shaken for 1-3 hrs, under nitrogen atmosphere. Coupling completion was monitored using a qualitative ninhydrin test. After the coupling of first amino acid, the resin was washed with DMF, DCM and Diethyl ether (50 ml X 4).
  • the Fmoc- protection on first amino acid, coupled with resin was deprotected, using a 10-20% piperidine solution, followed by the coupling the Fmoc-protected second amino acid, using a suitable coupling agents, and as described above.
  • the repeated cycles of deprotection, washing, coupling and washing were performed until the desired peptide chain was assembled on resin, as per general scheme above.
  • the desired peptidomimetics were cleaved and deprotected from their respective peptidyl-resins by treatment with TFA cleavage mixture as follows.
  • a solution of TFA / Water / Triisopropylsilane (95: 2.5: 2.5) (10 ml / 100 mg of peptidyl- resin) was added to peptidyl-resins and the mixture was kept at room temperature with occasional starring.
  • the resin was filtered, washed with a cleavage mixture and the combined filtrate was evaporated to dryness. Residue obtained was dissolved in 10 ml of water and the aqueous layer was extracted 3 times with ether (20 ml each) and finally the aqueous layer was freeze-dried.
  • Crude peptide obtained after freeze-drying was purified by preparative HPLC as f ⁇ ll ⁇ ws:
  • Preparative HPLC was carried out on a Shimadzu LC-8A liquid chromatograph.
  • a solution of crude peptide dissolved in DMF or water was injected into a semi-Prep column (Luna lO ⁇ ; C 18 ; 100 A 0 ), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 ml / min, with effluent monitoring by PDA detector at 220 ran.
  • a typical gradient of 20 % to 70 % of water- ACN mixture, buffered with 0.1 % TFA was used, over a period of 50 minutes, with 1% gradient change per minute.
  • the desired product eluted were collected in a single 10-20 ml fraction and pure peptidomimetics were obtained as amorphous white powders by lyophilisation of respective HPLC fractions.
  • HPLC analysis of the purified peptidomimetics were collected in
  • each peptide was analyzed by analytical RP-HPLC on a Shimadzu LC-IOAD analytical HPLC system.
  • analytical HPLC for analytic HPLC analysis of peptidomimetics, Luna 5 ⁇ ; C 18 ; 100 A ° , dimension 250 X 4.6 mm column was used, with a linear gradient of 0.1% TFA and ACN buffer and the acquisition of chromatogram was carried out at 220 nm, using a PDA detector. Characterization by Mass Spectrometry Each peptide was characterized by electrospray ionisation mass spectrometry
  • ESI-MS either in flow injection or LC/MS mode.
  • Triple quadrupole mass spectrometers API-3000 (MDS-SCIES, Canada) was used in all analyses in positive and negative ion electrospray mode. Full scan data was acquired over the mass range of quadrupole, operated at unit resolution. In all cases, the experimentally measured molecular weight was within 0.5 Daltons of the calculated monoisotopic molecular weight. Quantification of the mass chromatogram was done using Analyst 1.4.1 software.
  • the peptidomimetics prepared as described above were tested for GLP-I agonist activity in vitro using the cAMP cell-based assay described below.
  • the GLP-I mimetic peptide analog stimulated cAMP production in a dose response manner and the corresponding EC 50 value were determined for some of the selected peptidomimetics, which are active in vitro at 10 to 100 nM range.
  • the ECs 0 value of EX-4 was used as a positive control. Cyclic AMP determination
  • the GLP-I receptor is a G-protein coupled receptor.
  • GLP-I (7-36)-amide the biologically active form, binds to the GLP-I receptor and through signal transduction causes activation of adenylate cyclase and raises intracellular cAMP levels.
  • agonism of peptide compounds in stimulating the GLP-I receptor adenyl cyclase activity was monitored by assaying for cellular cAMP levels.
  • cAMP assay Stably transfected CHO/HGLP1R cells were assayed for cAMP generation in a semi high throughput platform using DiscoverX cAMP kit with Exendin-4 as a positive control.
  • NCEs The activity of NCEs was determined as % Exendin-4 activity at 0.0 l ⁇ M concentration.
  • the positive compounds were further validated for cAMP generation using indirect cAMP ELISA kit (R & D systems) The activity of the compounds was expressed as fmol cAMP/ ⁇ g of protein.
  • EC5 0 values of some of the representative compounds (I to IV) are shown in Figure 1. Demonstration of in vivo efficacy of compounds:
  • the in- vivo glucose lowering properties of some of the representative compounds in animal models is described below.
  • This test was used to examine in vivo efficacy of compounds of the present invention on blood glucose at hyperglycemia.
  • the intra peritoneal glucose tolerance test (IPGTT) was performed in overnight fasted Swiss Albino Mice (SAM), weighing 25-30 g. Mice were given glucose load of 1.5g/ Kg/ 10 ml and blood was collected at different time intervals, via retroorbital plexus.
  • Test compounds (peptidomimetics) were dissolved in an appropriate vehicle at a concentration in nmol/ ml equivalent to the dose that was to be administered in nmol / kg, so that each mouse would receive the same volume / weight of dosing solution.
  • AUC Area under the Curve
  • BCAUC Base line corrected area under the curve
  • the present invention provides novel GLP-I peptide mimics, with a preference for mimicking GLP-I, such that the compounds of the present invention have agonist activity for the GLP-I receptor. Further, many of the GLP peptide mimics of the present invention exhibit increased stability to proteolytic cleavage as compared to GLP-I native sequences.
  • the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating or delaying the progression or onset of diabetes (preferably type II, impaired glucose tolerance, insulin resistance and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts), hyperglycemia, hyperinsulinemia, hypercholesterolemia, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, hypertension, intestinal diseases (such as necrotizing enteritis, microvillus inclusion disease or celic disease).
  • the compound of the present invention may also be utilized to increase the blood levels of high density lipoprotein (HDL).
  • HDL high density lipoprotein
  • the conditions, diseases collectively referenced to as 'Syndrome X' or metabolic syndrome as detailed in Johannsson J., Clin. Endocrinol. Metab., 82, 727- 34,1997, may be treated employing the compounds of the invention.
  • the compounds of the present invention may optionally be used in combination with suitable DPP-IV inhibitors for the treatment of some of the above disease states either by administering the compounds sequentially or as a formulation containing the compounds of the present invention along with a suitable DPP-IV inhibitors.
  • the compounds of the present invention showed good glucose serum- lowering activity in the experimental animals used. These compounds are used for the testing/ prophylaxis of diseases caused by hyperinsulinaemia, hyperglycemia such as NIDDM, metabolic disorders and obesity since such diseases are inter-linked to each other.

Abstract

The present invention describes a group of novel peptidomimetics useful for the treatment of diabetes. These compounds are defined by the general formula (I) as given below. A-X1- S1-Y-S2-X2-B (I)

Description

NOVEL COMPOUNDS AS GLP-I AGONISTS Field of Invention
The present invention relates to novel compounds of general formula (I), their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them.
A-Xi- S1-Y-S2-X2-B (I)
In particular, the present invention relates to novel Glucagon-Like Peptide- 1 (GLP-I) peptide mimics (peptidomimetic), which act as GLP-I receptor agonists and exhibit most of the biological activity of the native GLP-I. Furthermore, these GLP-I peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme and can be delivered by both invasive and various non-invasive routes of administrations such as oral, nasal, buccal, pulmonary and transdermal route of administration, for the treatment or prevention of diabetes and related conditions.
The present invention also relates to a process of preparing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
Background to the invention
The GLP-I (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food. The physiological action of GLP-I has gained considerable interest. GLP-I exerts multiple action by stimulating insulin secretion from pancreatic β-cells, in a glucose dependent manner (insulinotropic action). GLP-I also lowers circulating plasma glucagon concentration, by inhibiting its secretion from α-cells (Drucker D. J., Endocrinology, 142, 521-527, 2001). More recently, it has become clear that GLP-I also exhibits properties like stimulation of β-cell growth, appetite suppression, delayed gastric emptying and stimulation of insulin sensitivity (Nauck, Horm. Metab. Res., 47, 1253-1258, 1997).
The venom of the GiIa Monster Heloderma Suspectuni contains a 39 amino acid peptide called Exendin-»4 (EX-4) that shares around 50 % sequence identity to GLP-I itself, exhibits a very potent GLP-IR (Glucagon like peptide-1 receptor) agonist activity (Thorens B., Diabetes, 42, 1678 - 1682, 1993). Indeed, it was found that EX-4 is much more potent than native GLP-I peptide, because of its relatively longer half- life (25 min., iv route of administration), compared to GLP-I (2-5 min., iv route of administration). Exendin-4 binds with greater affinity to the GLP-IR, due to presence of the nine extra C-terminal sequence (Doyle M.E., Regulatory Peptides, 114, 153-158, 2003). Thus, the above stated pharmacological properties of GLP-IR agonists make it a highly desirable therapeutic agent for the treatment of diabetes.
Native or synthetic GLP-I peptide is rapidly metabolized by the proteolytic enzymes, such as dipeptidyl peptidase-IV (DPP-IV) into an inactive metabolite, thereby limiting the use of GLP-I as a drug. Currently, various analogs of GLP-I and EX-4, such as Liraglutide / NN2211 (Novo Nordisk; Phase-Ill; WO 1998 008871), BIM 51077 (Ipsen; Phase-II; WO 2000 034331), CJC-1131 (ConjuChem; Phase-II; WO 2000 069911), ZP-10 (Zealand & Aventis; Phase-II; WO 2001 004156) are in different stages of clinical development (Nauck M. A., Regulatory Peptides, 115, 13-19, 2004). However, all these peptides require delivery via parenteral route of administration, including BYETTA® (Exendin-4, AC 2933; WO 2001 051078), which is recently launched in the market (Amylin & Lilly). Thus, there exists a critical need to develop a biologically active GLP-I mimic that possesses extended pharmacodynamic profiles.
The GLP-I R is a seven-transmembrane domain G-protein-coupled receptor (GPCR) and it is located on the cell membrane of pancreatic β-cells. The effector system of GLP-I R is the Adenylyl Cyclase (AC) enzyme. Interaction of GLP-I agonist with GLP-IR causes activation of AC, which converts ATP to cAMP. Increase in the intracellular cAMP level raises the ratio of ADP/ATP, thereby initiating the cell depolarization (due to closure of KATP channel). Increase in the intracellular cAMP level also activates Protein Kinase (PK-A & PK-C), which raises the cystolic Ca2+ concentration, by opening of L-type of Ca2+ channel. An increase in the intracellular Ca2+ leads to exocytosis of insulin, in pancreatic β-cells (Fehmann, H.C., Endocr. Rev., 16, 390 - 410, 1995).
A general mechanism of peptide ligand interaction with class-B GPCRs has emerged recently, termed the 'two-domain' model (Hoare S. R. J., Drug Discovery Today, Vol. 10 (6), 417-427, 2005). In this two-domain model, the C-terminal portion of the peptide binds to the N-domain of the receptor and the N-terminal ligand region binds to the J-domain (transmembrane) region of GPCR. This interaction activates the receptor and thereby stimulates intracellular signaling. The receptor binding and activation occurs in two separate domains of Exendin, but they are closely coupled in GLP-l (Eng J., J.B.C, 272 (34), 21291-21296, 1997). Prior art
Earlier, Bristol-Myers Squibb (BMS), Princeton, NJ (US), reported human GLP-I mimics, with general formula Xaal-Xaall, wherein Xaal-Xaa9 represent the first 1-9 residues of GLP-I peptide with some analogs wherein Xaa2 represents either Ala or is optionally replaced with Aib, and Xaa6 represents Phe or is optionally replaced with α-Me-Phe(2-F)-OH and XaalO & Xaall represents combination of substituted or unsubstituted biphenyl alanine (Bip) derivatives (WO 03/ 033671A2; US 2004/ 0127423 Al; WO 2004/ 094461 A2; US 2006 / 0004222 Al and WO 2006/ 014287 Al). The present invention provides novel GLP-I peptide mimics of formula (I)
(hereinafter referred to as peptidomimetics), which act as a GLP-IR agonist and exhibit most of the biological activity of the native GLP-I peptide. Furthermore, these GLP-I peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV enzyme and therefore, surprisingly found to have an increased half-life making them suitable for the treatment / mitigation / prophylaxis of both type 1 & type 2 diabetes, metabolic disorders, obesity and related disorders. Summary of the invention
The present invention describes a group of novel peptidomimetics useful for the treatment of diabetes. These compounds are defined by the general formula (I) as given below. The compounds of the present invention are useful in the treatment of the human or animal body, by regulation of insulin secretion. The compounds of this invention are therefore suitable for the treatment/mitigation/regulation or prophylaxis of both type 1 & type 2 diabetes and obesity.
Preferred embodiments
The main object of the present invention is to provide novel compounds of general formula (I), their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures, suitable for the treatment treatment/mitigation/regulation of diabetes.
In an embodiment is provided a process for the preparation of novel compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. In another embodiment, is provided pharmaceutical compositions containing compounds of general formula (I), their tautomeric forms, their pharmaceutically acceptable salts, solvates and their mixtures having pharmaceutically acceptable carriers, solvents, diluents, excipients and other media normally employed in their manufacture.
In a further another embodiment is provided the use of the novel compounds of the present invention as antidiabetic agents, by administering a therapeutically effective & non-toxic amount of the compound of formula (I), or their pharmaceutically acceptable compositions to the mammals those are need of such treatment. Abbreviations used
The following abbreviations are employed in the examples and elsewhere herein:
Aib = α-Aminoisobutyric acid,
ACN or MeCN = Acetonitrile, Bip = Biphenylalanine residue,
Bip(4-fluro)= 4-fluoro-biphenylalanine residue,
Bip(2-Me)= 2-methyl biphenyl residue,
Bip(2-Et)= 2-ethyl biphenyl residue,
Bip(2-CN)= 2-nitrile biphenyl residue, Bip(2-Ipr)= 2-Isopropyl biphenyl residue,
Bip(2'-Et-4'-OMe)= 2-ethyl-4-methoxy-biphenyl residue,
Bip(2-F)= 2-fluro-biphenyl residue,
Bn = Benzyl,
Boc = tert-Butoxycarbonyl, But= O-tert-butyl group, Adenosine 3 ',5 '-cyclic monophosphate,
DCM = Dichloromethane,
DMF = N,N-Dimethylformamide,
DIPCDI= Di-isopropylcarbodiimide, DIPEA= Diisopropylethylamine,
4-DBF=4-dibenzofuran-Phe-OH residue,
4-DBT=4-dibenzothiophene-Phe-OH residue,
Dihydro-Phen=2-(9, 10-Dihydro-phenanthrenyl] -AIa-OH residue,
Et = Ethyl, Et2O = Diethyl ether,
Fmoc = Fluorenylmethoxycarbonyl,
2-Flu=2-Fluorenyl-Ala-OH residue, g = Gram (s), GTT = Glucose Tolerance Test,
GLP-IR = Glucagon Like Peptide- 1 Receptor, h = Hour (s),
HOBt - Hydroxybenzotriazole,
HOAT= 7-Aza-hydroxybenzotriazole, HBTU = 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethyl aminium hexafluorophosphate,
HPLC = High Performance Liquid Chromatography,
L - Liter,
LC /MS = Liquid Chromatography / Mass Spectrometry,
4-(2'-Me-Ph)-3-Pyr-Ala= 4-(2'-methylphenyl)-3-pyridylalanine residue, Me = Methyl, .
Min = minute (s), ml = milliliter, μl = microliter, mg = milligram (s), mmol = millimole (s), fmol = fantomolar
MS= Mass Spectrometry,
1-Nap=4-(1-Naphthyl)-Phe residue,
2-Nap=4-(2-Naρhthyl)-Phe residue, Phen=2-(Phenanthrenyl)-Ala-OH residue,
Pbf= Pentamethylbenzofuran-5 -sulfonyl,
PyBOP = Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate,
SPPS = Solid Phase Peptide Synthesis,
Sc = sub-cutaneous, TrPh=4-phenyl-biphenylalanine residue,
TMS = Trimethylsilyl,
TIPS = Triisopropylsilane,
TFA = frifluoroacetic acid,
TBTU= 2-(lH-benzotriazole-l-yl)-l,l,3,3-tetramethylaminium tetrafluoroborate, Trt= Trityl group,
(α-Me)Phe(2-F)- a-methyl-2-fluoro-phenylalanine residue, -(N(Me))-= N-methylated amide bond,
D-Alanine represented by 'a' and D-Bip represent 'D'-Biphenyl alanine residue, ip = intra-peritoneal,
Sequence of GLP-I peptide =
NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-CONH2 (30 amino acids). The 30 amino acids of said GLP-I peptide are shown in Seq ID 1. HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR —Seq ID 1 Sequence of Exendin-4 =
NH2-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-CONH2 (39 amino acids). The 39 amino acids of Extendin -4 are shown in Seq ID 2. HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS —Seq ID 2
Detailed description
In accordance with the present invention, synthetic GLP-I analog peptides / peptidomimetics are provided, which have the structural formula (I),
Figure imgf000007_0001
wherein, A represents -NH-R1 , wherein R1 represents hydrogen, groups selected from linear or branched (C1-C15) alkyl chain, such as methyl, ethyl, propyl, isopropyl, n-butyl, iso- butyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, decyl groups and the like, an amino acid or peptide containing one, two or three natural amino acid residues, R3-CO- group, such as (2-Hydroxy-phenyl)-acetyl group and the like, R3O-C(O)- group, such as Fmoc group and the like, a sulfonyl group of formula R3-SO2-, each of these groups may be substituted, wherein R3 is selected from linear or branched (C1-C10) alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, decyl groups and the like, (C3-C6) cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl groups and the like, aryl groups selected from phenyl, napthyl, indanyl, fluorenyl, biphenyl and the like, heteroaryl groups selected from pyridyl, thienyl, furyl, imidzolyl, benzofuranyl and the like, arylalkyl groups selected from benzyl, naphthylmethyl and the like, each of these groups may be substituted; B represents -COOR2, -CONHR2 or CH2OR2, R2 represents H, groups selected from linear or branched (C1-C1O) alkyl group, such as methyl, ethyl, propyl, isopropyl, n- butyl, iso-butyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, decyl groups and the like, aryl groups selected from phenyl, napthyl, indanyl, fluorenyl, biphenyl and the like, aralkyl groups, each of these groups may be substituted, each of Si and S2 may independently be a bond or independently represents a group '- NH-(CH2)n-COO-', where, n=l-9; such as derivatives of amino acetic acid, amino propionic acid, amino butanoic acid, amino pentanoic acid, amino hexanoicacid, amino heptanoic acid, amino octanoic acid, amino-nonanoic acid, amino-decanoic acid and the like;
Y represents a bond or -CO-, -(CH2)m- (m = 1-3), 1O', 'S1, -CO-NH-, -CO-NR4-, or represents a short peptide containing one or two or three amino acids selected from natural or non-natural amino acids; where R4 represents H, optionally substituted groups selected from linear or branched (Ci-C10) alkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, isorbutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, decyl groups and the like, aryl groups selected from phenyl, napthyl, indanyl, fluorenyl, biphenyl and the like; with the proviso that i) when S1-Y-S2 represents a bond, X1 is selected from the following amino acid sequences HAEGTFTSD (Seq ID 3), HAEGTFTSDV (Seq ID 4), HAEGTFTSDVS (Seq ID 5),
HAEGTFTSDVSS (Seq ID 6), HAEGTFTSDVSSY (Seq ID 7), HAEGTFTSDVSSYL (Seq DD 8), HAEGTFTSDVS SYLE (Seq ID 9),
HAEGTFTSDVSSYLEG (Seq ID 10), HAEGTFTSDVS SYLEGQ (Seq ID 11),
HAEGTFTSDVSSYLEGQA (Seq JD 12), HAEGTFTSDVS SYLEGQAA (Seq ID 13), HAEGTFTSDVSSYLEGQAAK (Seq TD 14), HAEGTFTSDVS S YLEGQAAKE (Seq ID 15), HAEGTFTSDVSSYLEGQAAKEF (Seq ID 16),
HAEGTFTSDVSSYLEGQAAKEFI (Seq ID 17), with the further option that one or more of these amino acids may be replaced by unnatural amino acids, and X2 is selected from the following amino acid sequences GPSSGAPPPS (Seq ID 18)or KELEKLL (Seq ID 19)or GPPS or (Seq ID 20) VKGR (Seq ID 21); ii) and when SpY-S2 does not represent a bond X1 is selected from the following amino acid sequences
HA (Seq ID 22), HAE (Seq ID 23), HAEG (Seq ID 24), HAEGT (Seq ID 25), HAEGTF (Seq ID 26), HAEGTFT (Seq ID 27), HAEGTFTS (Seq ID 28), HAEGTFTSD (Seq ID 29) with the further option that one or more of these amino acids may be replaced by unnatural amino acids; X2 is selected from GPSSGAPPPS (Seq ID 18) or KELEKLL (Seq ID 19)or GPPS (Seq ID 20)or VKGR (Seq ID 21)or a dipeptide, selected from combination of two amino acids, consisting of natural or unnatural amino acids, having a side chain containing an arylalkyl or heteroarylalkyl moieties selected from benzyl, napthylmethyl, pyridylmethyl, thienylmethyl, furylmethyl, imidazolylmethyl, isooxazolylmethyl, quinolylmethyl, benzofuranylmethyl, benzothienylmethyl, indolinylmethyl, indolylmethyl, dibenzofuranylmethyl, dibenzothienylmethyl, benzodihydrofuranylmethyl, benzodihydrothienylmethyl, thienopyrimidylmethyl, benzimidazolylmethyl, phenanthrenylmethyl, dihydrophenanthrenylmethyl, fluorenylmethyl, dibenzofuranylmethyl, dibenzothiophenyl methyl groups and the like, where each of these groups may be optionally substituted with (Q-Cό^lkyl group such as methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, t-butyl, pentyl, isopentyl, hexyl groups and the like, (Ci-Ce)alkoxy group such as methoxy, ethoxy, propoxy, butoxy, pentoxy, hexanoxy groups, cyano, halo group such as chloro, bromo, iodo, fluoro groups, hydroxy or optionally substituted aryl or heteroaryl groups selected from phenyl, napthyl, pyridyl, thienyl, furyl, imidazolyl, isooxazolyl, quinolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, dibenzofuranyl, dibenzothienyl, benzodihydrofuranyl, benzodihydrothienyl, thienopyrimidyl, benzimidazolyl, phenanthrenyl, dihydrophenanthrenyl, fluorenyl, dibenzofuranyl, dibenzothiophenyl and the like, with the further provision that such aryl or heteroaryl substituents may further be optionally substituted with (Ci-Ce)alkyl,
Figure imgf000009_0001
cyano, halo, hydroxy or aryl or heteroaryl groups.
In a preferred embodiment, the dipeptide sequence may comprise of one or more amino acids selected from Bip, Bip(2-Me), Bip(2-Et), Bip(2-Ipr), Bip(2-CN), Bip(2'-Et-4'-OMe), B ip(4' -fluoro), Bip(4'-Phenyl), 2-(9,10-Dihydro-phenanthrenyl]- Ala, 2-(Phenanthrenyl)-Ala, 4-(2-Naphthyl)-Phe, 4-(l-Naphthyl)-Phe, 2-Fluorenyl-Ala, 4-dibenzofuran-Phe, 4-dibenzothiophene-Phe, 4-(2 ' -methylphenyl)-3 -pyridylalanine; The term 'natural amino acids' indicates all those twenty amino acids, which are present in nature. The term 'unnatural amino acids' or 'non-natural amino acids' represents either replacement of L-amino acids with corresponding D-amino acids such as replacement of L-AIa with D-AIa or L-Pro with D-Pro and the like or suitable modifications of the L or D amino acids, amino alkyl acids, either by
- α-alkylation such as substitution of Ala with α-methyl Ala (Aib), replacement of Phe with α-methyl Phe, replacement of substituted Bip with with α-methyl Bip;
- N-alkylation with groups selected from (C1-C6)alkyl or (C3-Ce)cycloalkyl groups;
- modification of side chain such as replacement of His with histidine analogs such as 1-imidazolyl-alanine (II) or des-amino-His,
Figure imgf000010_0001
or replacement of phenyl ring of Phe with pyridyl, napthyl, biphenyl groups;
- substitution on the side chain of amino acid such as substitution of aromatic amino acid side chain with halogen, (C1-C3)alkyl, aryl groups, more specifically the replacement of Phe with 2 & 4-halo Phe;
Such 'unnatural amino acids' or 'non-natural amino acids' may be represented generally by the following structure:
Figure imgf000010_0002
(Ha) wherein Rs is selected from H, F, (C1-Cs) alkyl, the stereochemical configuration at the carbon bearing R5 may be (R) or (S); R6 is selected from H or (C1-C3) alkyl; each of R7 and R8 is independently selected from H, (C1-C3) alkyl, such as methyl and ethyl or halogen atom, preferably fluorine atom; R9 represents groups, selected from (C1-Cs) alkyl, aryl or heteroryl moieties selected from phenyl, napthyl, pyridyl, thienyl, furyl, imidazolyl, isooxazolyl, quinolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, dibenzofuranyl, dibenzothienyl, benzodihydrofuranyl, benzodihydrothienyl, thienopyrimidyl, benzimidazolyl, phenanthrenyl, dihydrophenanthrenyl, fluorenyl, dibenzofuranyl, dibenzothiophenyl groups, where each of these groups may be optionally substituted with (Ci-C6)alkyl, (Ci-C6)alkoxy, cyano, halo, hydroxy or optionally substituted aryl or heteroaryl groups, with the further provision that such aryl or heteroaryl substituents may further be optionally substituted with (d-C6)alkyl, (C1- Cδ)alkoxy, cyano, halo, hydroxy or aryl or heteroaryl groups.
List of Fmoc protected Bip analogs used for the synthesis of GLP-I peptidomimetics
Figure imgf000012_0001
Figure imgf000012_0002
Fmoc-4-(2'-methylphenyl)-3-pyridylalanine-
Figure imgf000012_0003
4'-OMe)-OH Fmoc-Bip(2-CN)-OH
Figure imgf000012_0004
Fmoc-Bip(2-Me)-OH Fmoc-Bip-OH Fmoc-Bip(2-Ipr)-OH
Figure imgf000012_0005
Fmoc-Bip(4-Ph)-OH Fmoc-Bip(4-F)-OH Fmoc-2-(Phenanthrenyl)-Ala-OH
Figure imgf000012_0006
Fmoc-2-Fluorenyl-AIa-OH
Fmoc-4-dibenzofuran-Phe-OH
Fmoc-4-dibenzothiophene-Phe-OH
The suitable substituents include, but are not limited to the following radicals, alone or in combination with other radicals - hydroxyl, oxo, halo, thio, nitro, amino, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, carboxylic acid and its derivatives such as esters and amides;
The various groups, radicals and substituents used anywhere in the specification are described in the following paragraphs. The term "alkyl" used herein, either alone or in combination with other radicals, denotes a linear or branched radical containing one to ten carbons, such as methyl, ethyl, n-propyl, iyø-propyl, «-butyl, sec-butyl, tert-butyl, amyl, ?-amyi, «-pentyl, n- hexyl, wo-hexyl, heptyl, octyl, decyl and the like.
The term "cycloalkyl" used herein, either alone or in combination with other radicals, denotes a radical containing three to seven carbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
The term "aryl" or "aromatic" used herein, either alone or in combination with other radicals, denotes an aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused, such as phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl, and the like. ,
The term 'arylalkyl" denotes an alkyl group, as defined above, attached to an aryl, such as benzyl, phenylethyl, naphthylmethyl, and the like. The term "aryloxy" denotes an aryl radical, as defined above, attached to an alkoxy group, such as phenoxy, naphthyloxy and the like, which may be substituted. The term "aralkoxy" denotes an arylalkyl moiety, as defined above, such as benzyloxy, phenethyloxy, naphthylmethyloxy, phenylpropyloxy, and the like, which may be substituted.
The term "heteroaryl" or "heteroaromatic" used herein, either alone or in combination with other radicals, denotes an aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused containing one or more hetero atoms selected from O, N or S, such as pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidinyl, pyrazolopyrimidonyl, azaquinazolinyl, azaquinazolinoyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, thieήopyrimidonyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, quinazolonyl, pyrimidonyl, pyridazinyl, triazinyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzotriazolyl, phthalazynil, naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, and the like.
The term "heteroaralkyl" used herein, either alone or in combination with other radicals, denotes a heteroaryl group, as defined above, attached to a straight or branched saturated carbon chain containing 1 to 6 carbons, such as (2-furyl)methyl, (3- furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1 -methyl- 1 -(2- pyrimidyl)ethyl and the like. The terms "heteroaryloxy", "heteroaralkoxy", "heterocycloxy denotes heteroaryl, heteroarylalkyl, groups respectively, as defined above, attached to an oxygen atom. The term "acyl" used herein, either alone or in combination with other radicals, denotes a radical containing one to eight carbons such as formyl, acetyl, propanoyl, butanoyl, wo-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like, which may be substituted.
The term "carboxylic acid" used herein, alone or in combination with other radicals, denotes a -COOH group, and includes derivatives of carboxylic acid such as esters and amides. The term "ester" used herein, alone or in combination with other radicals, denotes -COO- group, and includes carboxylic acid derivatives, where the ester moieties are alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, and the like, which may be substituted. Unless otherwise indicated, the term 'amino acid' as employed herein alone or as part of another group includes, without limitation, an amino group and a carboxyl group linked to the same carbon, referred to as 'α' carbon.
The absolute 'S' configuration at the 'α' carbon is commonly referred to as the 'L' or natural configuration. The 'R' configuration at the 'α' carbon is commonly referred to as the 'D' amino acid. In the case where both the 'α-substituents' is equal, such as hydrogen or methyl, the amino acids are GIy or Λib and are not chiral.
The term 'receptor modulator' refers to a compound that acts at the GLP-I receptor to alter its ability to regulate downstream signaling events. Example of receptor modulators includes agonist, partial agonist, inverse agonist, allosteric potentiators.
Preferably, the isolated peptidomimetics are a 3-30 mer and such peptide bind to and activates the GLP-I receptor.
In accordance with the present invention, the synthetic isolated peptidomimetics described herein possess the ability to mimic the biological activity of GLP-I peptide, with preference for agonist activity at GLP-IR. These synthetic peptidomimetics GLP- 1 mimetic exhibit desirable in-vivo properties, thus making them ideal therapeutic candidates for oral or parenteral administration.
The present invention provides for compounds of formula (I) pharmaceutical compositions employing such compounds either alone or in combination and for methods of using such compounds. In particular, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I), alone or in combination(s), with a pharmaceutically acceptable carrier. Further provided is a method for treating or delaying the progression or onset of diabetes, especially type II diabetes, including complications of diabetes, including retinopathy, neuropathy, nephropathy and delayed wound healing and related diseases such as insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, hyperlipidemia including hypertriglyceridemia, syndrome X, atherosclerosis and hypertension, wherein a therapeutically effective amount of a compound of formula (I) or their combination(s) are administered to a mammal, example, human, a patient in need of treatment. Several synthetic routes can be employed to prepare the compounds of the present invention well known to one skilled in the art of peptide synthesis. The compounds of formula (I), where all symbols are as defined earlier can be synthesized using the methods described below, together with conventional techniques known to those skilled in the art of peptide synthesis, or variations thereon as appreciated by those skilled in the art. Referred methods include, but not limited to those described below. The peptidomimetics thereof described herein may be produced by chemical synthesis using suitable variations of various solid-phase techniques generally known such as those described in G. Barany & R. B. Merrifield, "The peptides: Analysis, synthesis, Biology"; Volume 2- "Special methods in peptide synthesis, Part A", pp. 3- 284, E. Gross & J. Meienhofer, Eds., Academic Press, New York, 1980; and in J. M. Stewart and J. D. Young, "Solid-phase peptide synthesis" 2nd Ed., Pierce chemical Co., Rockford, II, 1984.
The preferred strategy for preparing the peptidomimetics of this invention is based on the use of Fmoc-based SPPS approach, wherein Fmoc (9-Fluorenyl-methyl- methyloxycarbonyl) group is used for temporary protection of the α-amino group, in combination with the acid labile protecting groups, such as t-butyloxy carbonyl (Boc), tert-butyl (Bu4), Trityl (Trt) group for temporary protection of the amino acid side chains (see for example E. Atherton & R.C. Sheppard, "The Fluorenylmethoxycarbonyl amino protecting group", in "The peptides: Analysis, synthesis, Biology"; Volume 9 - "Special methods in peptide synthesis, Part C", pp. 1-38, S. Undenfriend & J. Meienhofer, Eds., Academic Press, San Diego, 1987).
Examples of orthogonally protected amino acids used in Fmoc-solid phase peptide synthesis for the synthesis of peptidomimetics
Figure imgf000016_0001
The peptidomimetics can be synthesized in a stepwise manner on an insoluble polymer support (resin), starting form the C-terminus of the peptide. In an embodiment, the synthesis is initiated by appending the C-terminal amino acid of the peptide to the resin through formation of an amide, ester or ether linkage. This allows the eventual release of the resulting peptide as a C-terminal amide, carboxylic acid or alcohol, respectively.
In the Fmoc-based SPPS, the C-terminal amino acid and all other amino acids used in the synthesis are required to have their α-amino groups and side chain functionalities (if present) differentially protected (orthogonal protection), such that the α-amino protecting group may be selectively removed during the synthesis, using suitable base such as 20% piperidine solution, without any premature cleavage of peptide from resin or deprotection of side chain protecting groups, usually protected with the acid labile protecting groups. The coupling of an amino acid is performed by activation of its carboxyl group as an active ester and reaction thereof with unblocked α-amino group of the N-terminal amino acid appended to the resin. After every coupling and deprotection, peptidyl-resin was washed with the excess of solvents, such as DMF, DCM and diethyl ether. The sequence of α-amino group deprotection and coupling is repeated until the desired peptide sequence is assembled. The peptide is then cleaved from the resin with concomitant deprotection of the side chain functionalities, using an appropriate cleavage mixture, usually in the presence of appropriate scavengers to limit side reactions. The resulting peptide is finally purified by reverse phase HPLC.
The synthesis of the peptidyl-resins required as precursors to the final peptides utilizes commercially available cross-linked polystyrene polymer resins (Novabiochem, San Diego, CA). Preferred for use in this invention are Fmoc-PAL-PEG-PS resin, 4-(2', 4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetyl-/7-methyl benzhydrylamine resin (Fmoc-Rink amide MBHA resin), 2-chloro-Trityl-chloride resin or p- benzyloxybenzyl alcohol resin (HMP resin) to which the C-terminal amino acid may or may not be already attached. If the C-terminal amino acid is not attached, its attachment may be achieved by HOBt active ester of the Fmoc-protected amino acid formed by its reaction with DIPCDI. In case of 2-Chloro-trityl resin, coupling of first Fmoc-protected amino acid was achieved, using DIPEA. For the assembly of next amino acid, N- terminal protection of peptidyl resin was selectively deprotected using a solution of 10- 20 % piperidine solution. After every coupling and deprotection, excess of amino acids and coupling reagents was removed by washed with a DMF, DCM and ether. Coupling of the subsequent amino acids can be accomplished using HOBt or HOAT active esters produced from DIPCDI/ HOBt or DIPCDI/HOAT, respectively. In case of some difficult coupling, especially coupling of those amino acids, which are hydrophobic or amino acids with bulky side chain protections, complete coupling can be achieved using a combination of highly efficient coupling agents such as HBTU, PyBOP or TBTU, with additives such as DIPEA.
General Scheme for Fmoc-Based SPPS:
Figure imgf000018_0001
20% Piperidine Deprotection
Figure imgf000018_0002
Acylation HOBt & DIPCDI
Figure imgf000018_0003
Figure imgf000018_0004
Deprotection
Aoylation
Final cleavage with TFA mixture
Peptide + Resin The synthesis of the peptide analogs described herein can be carried out by using batchwise or continuos flow peptide synthesis apparatus. The non-natural noncommercial amino acids present at different position were incorporated into the peptide chain, using one or more methods known in the art. In one approach, a Fmoc-protected non-natural amino acid was prepared in solution, using appropriate literature procedures. For example, the Fmoc-protected Bip analogs, described above, were prepared using modified Suzuki cross coupling method, as known in literature (for e.g. Tetrahedron Letter 58, 9633-9695, 2002). The Fmoc-protected α-methylated amino acids were prepared using asymmetric Strecker synthesis, as described for e.g. in Org. Letters 3(8), 1121-1124, 2001. The Fmoc-protected N-methylated amino acids were prepared using a literature method as described in for e.g. JOC, 2005, 70, 6918-6920. The resulting derivative was then used in the step-wise synthesis of the peptide. Alternatively, the required non-natural amino acid was built on the resin directly using synthetic organic chemistry procedures and a linear peptide chain were build. The peptide-resin precursors for their respective peptidomimetics may be cleaved and deprotected using suitable variations of any of the standard cleavage procedures described in the literature (see, for example, D. S. King et al. Int. J. peptide Protein res. 36, 1990, 255 - 266). A preferred method for use in this invention is the use of TFA cleavage mixture, in the presence of water and TIPS as scavengers. Typically, the peptidyl-resin was incubated in TFA / Water /TIPS (94:3:3; V: V: V; 10 ml / 100 mg of peptidyl resin) for 1.5-2 hrs at room temperature. The cleaved resin is then filtered off, the TFA solution is concentrated or dried under reduced pressure. The resulting crude peptide is either precipitated or washed with Et2O or is re-dissolved directly into DMF or 50 % aqueous acetic acid for purification by preparative HPLC. Peptidomimetics with the desired purity can be obtained by purification using preparative HPLC. The solution of crude peptide is injected into a semi-Prep column (Luna lOμ; C18; 100 A°), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 ml /min with effluent monitoring by PDA detector at 220 nm. The structures of the purified peptidomimetics can be confirmed by Electrospray Mass Spectroscopy (ES-MS) analysis.
All the peptide prepared were isolated as trifluoro-acetate salt, with TFA as a counter ion, after the Prep-HPLC purification. However, some peptides were subjected for desalting, by passing through a suitable ion exchange resin bed, preferably through anion-exchange resin Dowex SBR P(Cl) or an equivalent basic anion-exchange resin. In some cases, TFA counter ions were replaced with acetate ions, by passing through suitable ion-exchange resin, eluted with dilute acetic acid solution. For the preparation of the hydrochloride salt of peptides, in the last stage of the manufacturing, selected peptides, with the acetate salt was treated with 4 M HCl. The resulting solution was filtered through a membrane filter (0.2 μm) and subsequently
' lyophilized to yield the white to off-white HCl salt. Following similar techniques and/or such suitable modifications, which are well within the scope of persons skilled in the art, other suitable pharmaceutically acceptable salts of the peptidomimetics of the present invention were prepared. In a preferred embodiment, the present invention provides a method of making a peptidomimetics that mimics the activity of an endogenous polypeptide GLP-IR agonist. In another preferred embodiment, the polypeptide receptor agonist is GLP-I.
The novel compounds of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients as are well known.
The pharmaceutical composition is provided by employing conventional techniques. Preferably the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula (I) either alone or combination, according to this invention. The quantity of active component, that is, the compounds of formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. By way of guidance, the daily oral dosage of the active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day and most preferably between about 0.6 to 20 mg/kg/day.
General method of preparation of peptidomimetics, using SPPS approach: Assembly of peptidomimetics on resin: Sufficient quantity (50-100 mg) of Fmoc-P AL-PEG-PS resin or Fmoc-Rink amide MBHA resin, loading: 0.5-0.6 mmol / g was swelled in DMF (1-10 ml /100 mg of resin) for 2-10 minutes. The Fmoc-group on resin was then removed by incubation of resin with 10-30 % piperidine in DMF (10-30 ml / 100 mg of resin), for 10-30 minutes. Deprotected resin was filtered and washed excess of DMF, DCM and ether (50 ml X 4). Washed resin was incubated in freshly distilled DMF (1 ml / 100 mg of resin), under nitrogen atmosphere for 5 minutes. A 0.5 M solution of first Fmoc- protected amino acid (1-3 eq.), pre-activated with HOBt (1-3 eq.) and DIPCDI (1-2 eq.) in DMF was added to the resin, and the resin was then shaken for 1-3 hrs, under nitrogen atmosphere. Coupling completion was monitored using a qualitative ninhydrin test. After the coupling of first amino acid, the resin was washed with DMF, DCM and Diethyl ether (50 ml X 4). For the coupling of next amino acid, firstly, the Fmoc- protection on first amino acid, coupled with resin was deprotected, using a 10-20% piperidine solution, followed by the coupling the Fmoc-protected second amino acid, using a suitable coupling agents, and as described above. The repeated cycles of deprotection, washing, coupling and washing were performed until the desired peptide chain was assembled on resin, as per general scheme above.
Finally, the Fmoc-protected peptidyl-resin prepared above was deprotected by 20% piperidine treatment as described above and the peptidyl-resins were washed with DMF, DCM and Diethyl ether (50 ml X 4). Resin containing desired peptide was dried under nitrogen pressure for 10-15 minutes and subjected for cleavage/ deprotection. Cleavage and deprotection:
The desired peptidomimetics were cleaved and deprotected from their respective peptidyl-resins by treatment with TFA cleavage mixture as follows. A solution of TFA / Water / Triisopropylsilane (95: 2.5: 2.5) (10 ml / 100 mg of peptidyl- resin) was added to peptidyl-resins and the mixture was kept at room temperature with occasional starring. The resin was filtered, washed with a cleavage mixture and the combined filtrate was evaporated to dryness. Residue obtained was dissolved in 10 ml of water and the aqueous layer was extracted 3 times with ether (20 ml each) and finally the aqueous layer was freeze-dried. Crude peptide obtained after freeze-drying was purified by preparative HPLC as fυllυws:
Preparative HPLC purification of the crude peptidomimetics:
Preparative HPLC was carried out on a Shimadzu LC-8A liquid chromatograph. A solution of crude peptide dissolved in DMF or water was injected into a semi-Prep column (Luna lOμ; C18; 100 A0), dimension 250 X 50 mm and eluted with a linear gradient of ACN in water, both buffered with 0.1 % TFA, using a flow rate of 15 -50 ml / min, with effluent monitoring by PDA detector at 220 ran. A typical gradient of 20 % to 70 % of water- ACN mixture, buffered with 0.1 % TFA was used, over a period of 50 minutes, with 1% gradient change per minute. The desired product eluted were collected in a single 10-20 ml fraction and pure peptidomimetics were obtained as amorphous white powders by lyophilisation of respective HPLC fractions. HPLC analysis of the purified peptidomimetics
After purification by preparative HPLC as described above, each peptide was analyzed by analytical RP-HPLC on a Shimadzu LC-IOAD analytical HPLC system. For analytic HPLC analysis of peptidomimetics, Luna 5μ; C18; 100 A°, dimension 250 X 4.6 mm column was used, with a linear gradient of 0.1% TFA and ACN buffer and the acquisition of chromatogram was carried out at 220 nm, using a PDA detector. Characterization by Mass Spectrometry Each peptide was characterized by electrospray ionisation mass spectrometry
(ESI-MS), either in flow injection or LC/MS mode. Triple quadrupole mass spectrometers (API-3000 (MDS-SCIES, Canada) was used in all analyses in positive and negative ion electrospray mode. Full scan data was acquired over the mass range of quadrupole, operated at unit resolution. In all cases, the experimentally measured molecular weight was within 0.5 Daltons of the calculated monoisotopic molecular weight. Quantification of the mass chromatogram was done using Analyst 1.4.1 software.
Utilizing the synthetic methods described herein along with other commonly known techniques and suitable variations thereof, the following GLP-I peptidomimetics were prepared. This list is indicative of the various groups of peptidomimetics, which can be prepared according to the present invention, and are expected to at least include obvious variations of these compounds. However, such disclosure should not be construed as limiting the scope of the invention in any way. Table 1:
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000023_0002
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000025_0002
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
147 HAibEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
148 HAEG-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
149 HAibEG-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
The following compounds can be prepared according to the general processes described above and are included within the scope of the present invention (Tables 7-9) Table 7:
Figure imgf000034_0002
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
85 H-(N(Me))AEG-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr- AIa-NH2
86 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-Biρ(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3- Pyr-Ala-NH2
87 H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me- Ph)-3-Pyr-Ala-NH2
88 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me- Ph)-3-Pyr-Ala-NH2
89 H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH2
90 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))- 4-(2'-Me-Ph)-3-Pyr-Ala-NH2
91 Des-amino-H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
92 Des-amino-H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
93 H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
94 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))- 4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
95 H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)10-CH3
96 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))- 4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)10-CH3
97 CH3-(CH2)6-NH-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Mc-Ph)-3-Pyr-Ala-NII-(CH2)6-CH3
98 CH3-(CH2)6-NH-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
99 CH3-(CH2)10-NH-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
100 CH3-(CH2)10-NH-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
101 HAEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 102 H-Aib-EGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
103 HaEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
104 H-(N(Me))AEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
105 H-(N(Me))AEGT-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr- AIa-NH2
106 H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3- Pyr-Ala-NH2
107 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me- Ph)-3-Pyr-Ala-NH2
108 H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'- Me-Ph)-3-Pyr-Ala-NH2
109 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH2
110 H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
111 Des-amino-H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
112 Des-amino-H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
113 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
114 H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
115 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)10»CH3
116 H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)10-CH3
117 CH3-(CH2)6-NH-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
118 CH3-(CH2)6-NH-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
119 CH3-(CH2)io-NH-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'- OMe)-(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
Figure imgf000041_0001
Figure imgf000042_0001
Table 8:
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
The peptidomimetics prepared as described above were tested for GLP-I agonist activity in vitro using the cAMP cell-based assay described below. The GLP-I mimetic peptide analog stimulated cAMP production in a dose response manner and the corresponding EC50 value were determined for some of the selected peptidomimetics, which are active in vitro at 10 to 100 nM range. The ECs0 value of EX-4 was used as a positive control. Cyclic AMP determination
The GLP-I receptor is a G-protein coupled receptor. GLP-I (7-36)-amide, the biologically active form, binds to the GLP-I receptor and through signal transduction causes activation of adenylate cyclase and raises intracellular cAMP levels. To monitor agonism of peptide compounds in stimulating the GLP-I receptor, adenyl cyclase activity was monitored by assaying for cellular cAMP levels. cAMP assay: Stably transfected CHO/HGLP1R cells were assayed for cAMP generation in a semi high throughput platform using DiscoverX cAMP kit with Exendin-4 as a positive control. The activity of NCEs was determined as % Exendin-4 activity at 0.0 lμM concentration. The positive compounds were further validated for cAMP generation using indirect cAMP ELISA kit (R & D systems) The activity of the compounds was expressed as fmol cAMP/μg of protein. EC50 values of some of the representative compounds (I to IV) are shown in Figure 1. Demonstration of in vivo efficacy of compounds:
The in- vivo glucose lowering properties of some of the representative compounds in animal models is described below. This test was used to examine in vivo efficacy of compounds of the present invention on blood glucose at hyperglycemia. The intra peritoneal glucose tolerance test (IPGTT) was performed in overnight fasted Swiss Albino Mice (SAM), weighing 25-30 g. Mice were given glucose load of 1.5g/ Kg/ 10 ml and blood was collected at different time intervals, via retroorbital plexus. Test compounds (peptidomimetics) were dissolved in an appropriate vehicle at a concentration in nmol/ ml equivalent to the dose that was to be administered in nmol / kg, so that each mouse would receive the same volume / weight of dosing solution. Blood samples were drawn prior to Vehicle/Test compound/Glucose load (0 minute) and then at 15 min, 30 min, 60 min and 120 min. Vehicle/Test compound was administered 15 minutes prior to glucose load, via intra-peritoneal route of administration. Blood samples were centrifuged and the obtained serum was stored at - 20° C for analysis. Test compounds were examined along with a reference (positive control) and a vehicle control, with n = 6 animals per group. Glucose was determined by the GOD/POD method from serum. The mean value of duplicate results was calculated. The absolute values of glucose in serum levels were calculated using MS Excel software. The 0-minute base line corrected line graph were plotted using Graphpad prism software (ver 3.0). Area under the Curve (AUC) and Base line corrected area under the curve (BCAUC) were calculated and analyzed by performing One way ANOVA followed by Dunnett's post test using Graphpad prism software (ver 3.0).
Using above experimental protocol, in vivo glucose lowering properties of some of the selected compounds, which showed in vitro EC50, in CHO-GLP-IR cAMP assay, in the range of 1-50 nM range were determined. In Table 10, the in vivo glucose lowering potencies (ED50 in IPGTT SAM model) of selected four representative compounds (Comp. I, II, III & IV) were given. Table 10: In vivo potencies of compound I to IV (EDS0), in IPGTT SAM Model
Figure imgf000053_0001
Several compounds of the present invention were screened in vivo, using other animal models, such as ob/ob, db/db and C57 and they showed in vivo efficacy and potency in varying degrees. Utilities: The present invention provides novel GLP-I peptide mimics, with a preference for mimicking GLP-I, such that the compounds of the present invention have agonist activity for the GLP-I receptor. Further, many of the GLP peptide mimics of the present invention exhibit increased stability to proteolytic cleavage as compared to GLP-I native sequences. Accordingly, the compounds of the present invention can be administered to mammals, preferably humans, for the treatment of a variety of conditions and disorders, including, but not limited to, treating or delaying the progression or onset of diabetes (preferably type II, impaired glucose tolerance, insulin resistance and diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts), hyperglycemia, hyperinsulinemia, hypercholesterolemia, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, hypertension, intestinal diseases (such as necrotizing enteritis, microvillus inclusion disease or celic disease). The compound of the present invention may also be utilized to increase the blood levels of high density lipoprotein (HDL).
In addition, the conditions, diseases collectively referenced to as 'Syndrome X' or metabolic syndrome as detailed in Johannsson J., Clin. Endocrinol. Metab., 82, 727- 34,1997, may be treated employing the compounds of the invention. The compounds of the present invention may optionally be used in combination with suitable DPP-IV inhibitors for the treatment of some of the above disease states either by administering the compounds sequentially or as a formulation containing the compounds of the present invention along with a suitable DPP-IV inhibitors.
No adverse effects were observed for any of the mentioned compounds of invention. The compounds of the present invention showed good glucose serum- lowering activity in the experimental animals used. These compounds are used for the testing/ prophylaxis of diseases caused by hyperinsulinaemia, hyperglycemia such as NIDDM, metabolic disorders and obesity since such diseases are inter-linked to each other.

Claims

JJO-CHO-^JOUUWe claim:
1. An isolated polypeptide having a sequence of Formula (I), including its tautomers, solvates and pharmaceutically acceptable salts
A-Xi- S1-Y-S2-X2-B (I) wherein,
A represents -NH-R1, wherein R1 represents hydrogen, groups selected from linear or branched (C1-C1S) alkyl chain, an amino acid or peptide containing one, two or three natural amino acid residues, R3-CO- group, RsO-C(O)- group, a sulfonyl group of formula Rs-SO2-, each of these groups may be substituted; R3 is selected from linear or branched (C1-C1O) alkyl, (C3-C6) cycloalkyl, aryl, heteroaryl, arylalkyl groups, each of these groups may be substituted;
B represents -COOR2, -CONHR2 or CH2OR2, R2 represents H, groups selected from linear or branched (Ci-C10) alkyl, aryl groups selected from phenyl, napthyl, indanyl, fluorenyl, biphenyl groups, aralkyl group, wherein the aryl groups are as defined earlier, each of these groups may be substituted; each of S1 and S2 may independently be a bond or independently represents a group '- NH-(CH2)n-C00-', where, n=l-9;
Y represents a bond or -CO-, -(CH2)m- (m = 1-3), '0', 1S', -CO-NH-, -CO-NR4-, or represents a short peptide containing one or two or three amino acids selected from natural or non-natural amino acids; where R4 represents H, optionally substituted groups selected from linear or branched (C1-C1O) alkyl or aryl groups selected from phenyl, napthyl, indanyl, fluorenyl, biphenyl groups; with the proviso that when S1-Y- S2 represents a bond, X1 is selected from the following amino acid sequences HAEGTFTSD, HAEGTFTSDV, HAEGTFTSDVS, HAEGTFTSDVSS, HAEGTFTSDVSSY, HAEGTFTSDVSSYL, HAEGTFTSDVSSYLE,
HAEGTFTSDVSSYLEG, HAEGTFTSDVSSYLEGQ, HAEGTFTSDVSSYLEGQA, HAEGTFTSDVSSYLEGQAA, HAEGTFTSDVSSYLEGQAAK,
HAEGTFTSDVSSYLEGQAAICE, HAEGTFTSDVSSYLEGQAAKEF, HAEGTFTSDVSSYLEGQAAKEFI, with the further option that one or more of these amino acids may be replaced by unnatural amino acids, and X2 is selected from the following amino acid sequences GPSSGAPPPS or KELEKLL or GPPS or VKGR; and when S1-Y-S2 does not represent a bond X1 is selected from the following amino acid sequences HA, HAE, HAEG, HAEGT, HAEGTF, HAEGTFT, HAEGTFTS, HAEGTFTSD with the further option that one or more of these amino acids may be replaced by unnatural amino acids; X2 is selected from GPSSGAPPPS or KELEKLL or GPPS or VKGR or a dipeptide, selected from combination of two amino acids consisting of natural or unnatural amino acids, having a side chain containing an arylalkyl or heterorylalkyl moieties selected from benzyl, napthylmethyl, pyridylmethyl, thienylmethyl, furylmethyl, imidazolylmethyl, isooxazolylmethyl, quinolylmethyl, benzofuranylmethyl, benzothienylmethyl, indolinylmethyl, indolylmethyl, dibenzofuranylmethyl, dibenzothienylmethyl, benzodihydrofuranylmethyl, benzodihydrothienylmethyl, thienopyrimidylmethyl, benzimidazolylmethyl, phenanthrenylmethyl, dihydrophenanthrenylmethyl, fluorenylmethyl, dibenzofuranylmethyl, dibenzothiophenyl methyl groups, where each of these groups may be optionally substituted with (C1-C6)alkyl, (Q-C^alkoxy, cyano, halo, hydroxy or optionally substituted aryl or heteroaryl groups, with the further provision that such aryl or heteroaryl substituents may further be optionally substituted with (Cj-C6)alkyl, (Ci-C6)alkoxy, cyano, halo, hydroxy or aryl or heteroaryl groups.
2. A compound as claimed in claim 1 wherein the non-natural amino acids are represented by the general formula (Ha)
Figure imgf000056_0001
wherein R5 is selected from H, F, (C1-Cs) alkyl, the stereochemical configuration at the carbon bearing R5 may be (R) or (S); R6 is selected from H or (C1-C3) alkyl; each of R7 and R$ is independently selected from H, (C1-C2) alkyl or halogen atom, preferably fluorine atom; R9 represents groups, selected from (C1-Cs) alkyl, aryl or heteroryl moieties selected from phenyl, napthyl, pyridyl, thienyl, furyl, imidazolyl, isooxazolyl, quinolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, dibenzofuranyl, dibenzothienyl, benzodihydrofuranyl, benzodihydrothienyl, thienopyrimidyl, benzimidazolyl, phenanthrenyl, dihydrophenanthrenyl, fluorenyl, dibenzofuranyl, dibenzothiophenyl groups, where each of these groups may be optionally substituted with (C1-C6) alkyl, (C1-C6) alkoxy, cyano, halo, hydroxy or optionally substituted aryl or heteroaryl groups, with the further provision that such aryl or heteroaryl substituents may further be optionally substituted with (C1- C6)alkyl, (d-C6)alkoxy, cyano, halo, hydroxy or aryl or heteroaryl groups.
3. The isolated peptide as claimed in claim 1, wherein the dipeptide representing X2 is preferably selected from Bip, Bip(2-Me), Biρ(2-Et), Bip(2-Ipr), Bip(2-CN), Bip(2'- Et-4'-OMe), Bip(4'-fluoro), Bip(4'-Phenyl), 2-(9,10-Dihydro-phenanthrenyl]-Ala, 2-(Phenanthrenyl)-Ala, 4-(2-Naphthyl)-Phe, 4-(l-Naphthyl)-Phe, 2-Fluorenyl-Ala, 4-dibenzofuran-Phe, 4-dibenzothiophene-Phe, 4-(2'-methylρhenyl)-3-pyridylalanine groups.
4. The isolated peptide as claimed in claim 1, wherein the substituents are selected from hydroxyl, oxo, halo, thio, nitro, amino, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, aryl, aryloxy, aralkyl, aralkoxy, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, carboxylic acid and its derivatives selected from esters and amides.
5. The isolated polypeptide of claim 1, wherein the isolated polypeptide is a compound selected from HGEGTFTSD-(CH2)3-GPSSGAPPPS
HGEGTFTSD-(CH2)4-GPSSGAPPPS HGEGTFTSD-(CH2)s-GPSSGAPPPS HGEGTFTSD-(CH2)6-GPSSGAPPPS HGEGTFTSD-(CH2)7-GPSSGAPPPS HGEGTFTSD-(CH2)10-GPSSGAPPPS
HGEGTFTSD-(CH2)n-GPSSGAPPPS
HGEGTFTSDLSKQM-(CH2)3-GPSS
HGEGTFTSDLSKQM-(CH2)4-GPSS HGEGTFTSDLSKQM-(CH2)5-GPSS
HGEGTFTSDLSKQM-(CH2)6-GPSS
HGEGTFTSDLSKQM-(CH2)7-GPSS
HGEGTFTSDLSKQM-(CH2)IO-GPSS
HGEGTFTSDLSKQM-(CH2)Π-GPSS HGEGTFTSDLSKQME-G-GPSSGAPPP1S
HGEGTFTSDLSKQME-(CH2)2-GPSSGAPPPS
HGEGTFTSDLSKQME-(CH2)3-GPSSGAPPPS
HGEGTFTSDLSKQME-(CH2)4-GPSSGAPPPS
HGEGTFTSDLSKQME-(CH2)5-GPSSGAPPPS HGEGTFTSDLSKQME-(CH2)6-GPSSGAPPPS
HGEGTFTSDLSKQME-(CH2)7-GPSSGAPPPS
HGEGTFTSDLSKQME-(CH2)1o-GPSSGAPPPS
HGEGTFTSDLSKQME-(CH2)π-GPSSGAPPPS
HAEGTFTSD-(CH2)2-VKGR HAEGTFTSD-(CH2)3-VKGR
HAEGTFTSD-(CH2)4-VKGR
HAEGTFTSD-(CH2)5-VKGR
HAEGTFTSD-(CH2)6-VKGR
HAEGTFTSD-(CH2)IO-VKGR HAibEGTFTSD-(CH2)2-VKGR
HAibEGTFTSD-(CH2)3-VKGR
HAibEGTFTSD-(CH2)4-VKGR
HAibEGTFTSD-(CH2)s-VKGR
HAibEGTFTSD-(CH2)6-VKGR HAibEGTFTSD-(CH2)10-VKGR
HGEGTFTSDLSKQMKELEKLL
HAEGTFTSDKELEKLL
HGEGTFTSDKELEKLL
HAibEGTFTSDGKELEKLL HGEGTFTSDGKELEKLL HGEGTFTSDVSKELEKLL HAEGTFTSDVSKELEKLL HAEGTFTSDVSEKELEKLL HAEGTFTSDVSGKELEKLL
HAEGTFTSDVSSYLEKELEKLL HAEGTFTSDVSSYLEGKELEKLL HGEGTFTSDVSSYLEGKELEKLL HaEGTFTSDVSSYLEGKELEKLL HAibEGTFTSDVSSYLEGKELEKLL
HAEGTFTSDVSSYLEGKELEKLLVKG HAEGTFTSDVSSYLEPKELEKLL HAEGTFTSDVSSYLEGQAAKELEKLL HAEGTFTSDVSSYLEGQAAKEFIKELEKLL HAIBEGTFTSDVSSYLEGQAAKEFIKELEKLL
HAibEGT-(α-Me)Phe(2-F)-TSDVSSYLEGQAAKEFIKELEKLL
Des-amino-HAibEGT-(α-Me)Phe(2-F)-TSDVSSYLEGQAAKEFIKELEKLL
HAEGTFTSD-(CH2)3-KELEKLL
HAEGTFTSD-(CH2)4-KELEKLL HAEGTFTSD-(CH2)S-KELEKLL
HAEGTFTSD-(CH2)6-KELEKLL
HA-(CH2)3-DVSSYLEGQAAKEFIKELEKLL
HAib-(CH2)3-DVSSYLEGQAAKEFIKELEKLL
HAibEGTFTSDVSSYLEGQ-(CH2)2-KELEKLL HAibEGTFTSDVSSYLEGQ-(CH2)3-KELEKLL
HAibEGTFTSDVSSYLE-(CH2)2-FIKELEKLL
HGEGTFTSD-(CH2)3-Bip-Bip
HAibEGTFTSD-(CH2)3-Bip-Bip
HAibEGT-(α-Me)-Phe(2-F)-TSD-(CH2)3-Bip-Bip HAEGTFTSD-G-Bip(2-Me)-Bip(2-Me)
HAibEGTFTSD-G-Bip(2-Me)-Bip(2-Me)
HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Biρ(2-Me)-Bip(2-Me)
HAEGTFTS-G-Bip(2-Me)-Bip(2-Me)
HAibEGTFTS-G-Bip(2-Me)-Bip(2-Me) HAibEGT-(α-Me)-Phe(2-F)-TS-G-Bip(2-Me)-Bip(2-Me)
HAEGTFTS-(CH2)2-Biρ(2-Me)-Bip(2-Me)
HAibEGTFTS-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGT-(α-Me)-Phe(2-F)-TS-(CH2)2-Bip(2-Me)-Bip(2-Me) HAEGTFT-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGTFT-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGT-(α-Me)-Phe(2-F)-T-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAEGTF-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGTF-(CH2)2-Bip(2-Me)-Bip(2-Me) HAibEGT-(α-Me)-Phe(2-F)-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAEGT-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGT-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAEG-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEG-(CH2)2-Bip(2-Me)-Bip(2-Me) HAEGTFTSD-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGTFTSD-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAibEGT-(α-Me)-Phe(2-F)-TSD-(CH2)2-Bip(2-Me)-Bip(2-Me)
HAEGTFTSD-G-Bip-Bip(2-Me)
HAibEGTFTSD-G-Bip-Bip(2-Me) HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip-Bip(2-Me)
HAEGTFTSD-G-Bip(2-Me)-Bip
HAibEGTFTSD-G-Bip(2-Me)-Bip
HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Me)-Bip
HAEGTFTSD-G-Bip-Bip HAibEGTFTSD-G-Bip-Bip HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Biρ-Bip
HAEGTFTSD-G-Bip-Bip(2-Et)
HAibEGTFTSD-G-Bip-Bip(2-Et)
HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip-Bip(2-Et)
HAEGTFTSD-G-Bip(2-Et)-Bip(2-Et) HAibEGTFTSD-G-Bip(2-Et)-Biρ(2-Et)
HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Et)-Bip(2-Et)
HAEGTFTSD-G-Bip(2-Et)-Bip
HAibEGTFTSD-G-Bip(2-Et)-Bip HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Et)-Bip HAEGTFTSD-G-Bip(2-Et)-Bip(2-Me) HAibEGTFTSD-G-Bip(2-Et)-Bip(2-Me) HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Et)-Bip(2-Me) HAEGTFTSD-G-Bip(2-Me)-Bip(2-Et)
HAibEGTFTSD-G-Bip(2-Me)-Bip(2-Et) HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Me)-Bip(2-Et) HGEGTFTSD-G-Bip(2-Me)-Bip(2-Me) HGEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Me)-Bϊp(2-Me) HGEGTFTSD-G-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-Et)-Bip(2-Et) HGEGTFTSD-(CH2)3-Bip(2-Me)-Bip(2-Me) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)3-Bip(2-Me)-Bip(2-Me) HGEGTFTSD-(CH2)4-Bip(2-Me)-Bip(2-Me) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)4-Bip(2-Me)-Bip(2-Me)
HGEGTFTSD-(CH2)5-Bip(2-Me)-Bip(2-Me) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)5-Bip(2-Me)-Bip(2-Me) HGEGTFTSD-(CH2)6-Bip(2-Me)-Bip(2-Me) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)6-Bip(2-Me)-Bip(2-Me) HGEGTFTSD-(CH2)10-Bip(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)10-Bip(2-Me)-Bip(2rMe) HGRCτTFTSD-(CH2)3-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)3-Bip(2-Et)-Bip(2-Et) HGEGTFTSD-(CH2)4-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)4-Bip(2-Et)-Bip(2-Et)
HGEGTFTSD-(CH2)5-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)5-Bip(2-Et)-Bip(2-Et) HGEGTFTSD-(CH2)6-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)6-Bip(2-Et)-Bip(2-Et) HGEGTFTSD-(CH2)10-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)io-Bip(2-Et)-Bip(2-Et) HGEGTFTSD-(CH2)! i-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)π-Bip(2-Et)-Bip(2-Et) HGEGTFTS-(CH2)3-Bip(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)3-Bip(2-Me)-Bip(2-Me)
HGEGTFTS-(CH2)4-Bip(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)4-Bip(2-Me)-Bip(2-Me) HGEGTFTS-(CH2)5-Bip(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)5-Bip(2-Me)-Bip(2-Me)
HGEGTFTS-(CH2)6-Bip(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)6-Bip(2-Me)-Bip(2-Me)
HGEGTFTS-(CH2)io-Bip(2-Me)-Bip(2-Me) HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)io-Bip(2-Me)-Bip(2-Me)
HGEGTFTS-(CH2)π-Biρ(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)n-Bip(2-Me)-Bip(2-Me)
HGEGTFTS-(CH2)3-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)3-Bip(2-Et)-Biρ(2-Et) HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)4-Bip(2-Et)-Bip(2-Et)
HGEG1TTS-(CH2)4-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)4-Bip(2-Et)-Bip(2-Et)
HGEGTFTS-(CH2)5-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)5-Bip(2-Et)-Bip(2-Et) HGEGTFTS-(CH2)6-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)6-Bip(2-Et)-Bip(2-Et)
I-IGEGTFTS-(CII2)lϋ-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)10-Bip(2-Et)-Bip(2-Et)
HGEGTFTS-(CH2)π-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)j rBip(2-Et)-Bip(2-Et)
HGEGTFTS-(CH2)2-Bip(2-Me)-Bip(2-Me)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)2-Bip(2-Me)-Bip(2-Me)
HGEGTFTS-(CH2)2-Bip(2-Et)-Bip(2-Et)
HGEGT-(α-Me)-Phe(2-F)-TS-(CH2)2-Bip(2-Et)-Biρ(2-Et) HAEGTFTS-(CH2)2-Bip(2-Et)-Bip(2-Et)
HAibEGTFTS-(CH2)2-Bip(2-Et)-Bip(2-Et)
HAibEGT-(α-Me)-Phe(2-F)-TS-(CH2)2-Bip(2-Et)-Bip(2-Et)
HGEGTFTSD-(CH2)2-Bip(2-Et)-Bip(2-Et) HGEGT-(α-Me)-Phe(2-F)-TSD-(CH2)2-Bip(2-Et)-Bip(2-Et)
HAEGTFTSD-(CH2)2-Bip(2-Et)-Bip(2-Et)
HAibEGTFTSD-(CH2)2-Bip(2-Et)-Bip(2-Et)
HAibEGT-(α-Me)-Phe(2-F)-TSD-(CH2)2-Bip(2-Et)-Bip(2-Et) HAEGTF-(CH2)2-Biρ(2-Me)-Bip(2-Et)
HAibEGTF-(CH2)2-Bip(2-Me)-Bip(2-Et)
HAibEGT-(α-Me)-Phe(2-F)-(CH2)2-Bip(2-Me)-Bip(2-Et)
HAEGTFTSD-G-TrPh-TrPh
HAibEGTFTSD-G-TrPh-TrPh HAibEGT-(α-Me)-Phe(2-F)-TSD-G-TrPh-TrPh
HAibEGT-(α-Me)-Phe(2-F)-(CH2)2-TrPh-TrPh
HAibEG-(CH2)2-TrPh-TrPh
HAibE-(CH2)2-TrPh-TrPh
HAib-(CH2)3-TrPh-TrPh HAEGTFTSD-G-Nap-Nap
HAibEGTFTSD-G-Naρ-Nap
HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Nap-Nap
HAEGTFTSD-G-Bip(2-F)-Bip(2-F)
HAibEGTFTSD-G-Bip(2-F)-Bip(2-F) AibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2-F)-Bip(2-F)
HAEGTFTSD-G-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGTFTSD-G-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGT-(α-Me)-Phe(2-F)-TSD-G-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAEGTFTSD-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala HAibEGTFTSD-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGT-(α-Me)-Phe(2-F)-TSD-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa
HAEGTFTS-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGTFTS-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala HAibEGT-(α-Me)-Phe(2-F)-TS-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
Ala HAEGTFT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGTFT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala HAibEGT-(α-Me)-Phe(2-F)-T-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAEGTF-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGTF-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGT-(α-Me)-Phe(2-F)-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala HAEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAibEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAEG-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala HAibEG-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala
HAEGT-(CH2)2-Bip(2-Me)-Bip(2-Me)
HGEGT-(CH2)3-Bip(2-Me)-Bip(2-Me)
HGEGT-(CH2)4-Bip(2-Me)-Bip(2-Me)
HGEGT-(CH2)5-Bip(2-Me)-Bip(2-Me) HGEGT-(CH2)6-Bip(2-Me)-Bip(2-Me)
HAEGT-(CH2)2-Bip(2-Me)-DBiρ(2-Me)
HAEGT-(CH2)2-DBip(2-Me)-Bip(2-Me)
HaEGT-(CH2)2-Bip(2-Me)-Bip(2-Me)
HGEG-(CH2)3-Bip(2-Me)-Bip(2-Me) HAEG-(CH2)3-Bip(2-Me)-Bip(2-Me)
HGEG-(CH2)4-Bip(2-Me)-Bip(2-Me)
HGEG-(CH2)5-Bip(2-Me)-Bip(2-Me)
HGEG-(CH2)0-Biρ(2-Me)-Bip(2-Me)
HAEG-(CH2)3-Bip(2-Et)-Biρ(2-Me) HAEG-(CH2)3-Bip(2-Me)-DBip(2-Me)
HAEG-(CH2)4-Bip(2-Me)-DBip(2-Me)
HAEG-(CH2)5-Biρ(2-Me)-DBip(2-Me)
HGEG-(CH2)5-DBip(2-Me)-Bip(2-Me)
HAE-(CH2)3-Bip(2-Me)-Bip(2-Me) HAE-(CH2)3-Bip(2-Me)-DBiρ(2-Me)
HAE-(CH2)2-D-Biρ(2-Me)-Bip(2-Me)
HAE-(CH2)3-D-Bip(2-Me)-Bip(2-Me)
HAE-(CH2)4-D-Biρ(2-Me)-Bip(2-Me)
HAE-(CH2)4-Biρ(2-Me)-DBiρ(2-Me) HAE-(CH2)5-D-Bip(2-Me)-Bip(2-Me)
HAE-(CH2)3-Biρ(2-Et)-Bip(2-Me)
HAE-(CH2)2-Bip(2-Me)-Bip(2-Me)
H-(CH2)3-Bip(2-Me)-Bip(2-Me) H-(CH2)4-Bip(2-Me)-Bip(2-Me)
H-(CH2)5-Bip(2-Me)-Bip(2-Me)
H-(CH2)3-Bip(2-Et)-Bip(2-Me)
H-(CH2)4-Bip(2-Et)-Bip(2-Me)
H-(CH2)5-Bip(2-Et)-Bip(2-Me) H-(CH2)6-Bip(2-Et)-Biρ(2-Me)
H-(CH2)10-Bip(2-Et)-Bip(2-Me)
H-(CH2)5-Bip(2-Me)-DBip(2-Me)
H-(CH2)5-DBip(2-Me)-Bip(2-Me)
H-(CH2)5-DBip(2-Me)-DBip(2-Me) HG-(CH2)3-Bip(2-Me)-Bip(2-Me)
HG-(CH2)4-Bip(2-Me)-Bip(2-Me)
HG-(CH2)3-Bip(2-Et)-Bip(2-Me)
HG-(CH2)4-Bip(2-Et)-Bip(2-Me)
HG-(CH2)3-Bip(2-Et)-DBip(2-Me) HG-(CH2)3-Bip(2-Me)-DBip(2-Me)
FA-(CH2)3-DBip(2-Me)-Bip(2-Et)
FA-(CH2)3-DBip-Dbip
Ha-(CH2)3-Bip(2-Me)-Bip(2-Me)
Ha-(CH2)4-Bip(2-Me)-Bip(2-Me) Ha-(CH2)5-Bip(2-Me)-Bip(2-Me)
Ha-(CH2)3-Bip(2-Et)-Bip(2-Me)
Ha-(CH2)3-Bip(2-Et)-DBiρ(2-Me)
Ha-(CH2)3-Bip(2-Me)-DBip(2-Me)
Ha-(CH2)3-Blp(2-Et)-DBip(2-Et) Ha-(CH2)3-Bip(2-Me)-Bip
Ha-(CH2)3-(N(Me))-DBip(2-Me)-Bip(2-Et)
Ha-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)
Ha-(CH2)3-(N(Me))-DBip-Bip(2-Et)
Ha-(CH2)3-DBip(2-Me)-Bip(2-Et) HA-(CH2)3-Bip(2-Me)-Bip(2-Me)
HA-(CH2)4-Bip(2-Me)-Bip(2-Me)
HA-(CH2)5-Bip(2-Me)-Biρ(2-Me)
HA-(CH2)6-Bip(2-Me)-Bip(2-Me) HA-(CH2)i0-Bip(2-Me)-Bip(2-Me)
HA-(CH2)! 1-Bip(2-Me)-Bip(2-Me)
HA-(CH2)3-Bip(2-Et)-Bip(2-Me)
HA-(CH2)3-Bip(2-Et)-DBip(2-Et)
HA-(CH2)3-DBip(2-Me)-DBip(2-Me) HA-(CH2)3-DBip(2-Me)-Bip(2-Me)
HA-(CH2)3-Bip(2-Me)-DBip(2-Me)
HA-(CH2)3-Bip(2-Ipr)-Bip(2-Ipr)
HA-(CH2)3-Bip(2-Ipr)-Bip(2-Me)
HA-(CH2)3-Bip(2-Me)-Bip(2-Ipr) HA-(CH2)4-Bip(2-Et)-Bip(2-Me)
HA-(CH2)3-Bip(2-Me)-DBip(2-Et)
HA-(CH2)2-Bip(2-Et)-Bip(2-Me)
HA-(CH2)5-Bip(2-Et)-Bip(2-Me)
HA-(CH2)6-Bip(2-Et)-Bip(2-Me) HA-(CH2)2-Bip(2-Me)-Bip(2-Me)
HA-(CH2)3-DBip(2-Et)-DBip(2-Me)
HA-(CH2)3-DBip(2-Et)-Biρ(2-Me)
HA-(CH2)2-Bip(2-Me)-DBip(2-Me)
HA-(CH2)3-Bip(2-Et)-Bip(2-Et) HA-(CH2)3-DBip(2-Et)-DBiρ(2-Et)
HA-(CH2)3-DBip(2-Et)-Biρ(2-Et)
HA-(CH2)3-DBip(2-Me)-DBip(2-Et)
HA-(CH2)3-Bip(2-Me)-Bip(2-Et)
HA-(CH2)3-DBip(2-Me)-Bip(2-Et) HA-(CH2)3-Bip-Bip
HA-(CH2)3-Bip-D-Bip
HA-(CH2)3-DBip-D-Bip
HA-(CH2)3-DBip-Bip
HA-(CH2)3-Bip-Bip(2-Me) HA-(CH2)3-Bip(2-Me)-Bip
HA-(CH2)3-Bip(2-Et)-Bip
HA-(CH2)3-Bip-Bip(2-Et)
HA-(CH2)3-Bip(2-Ipr)-DBip(2-Iρr) HA-(CH2)3-DBip(2-Ipr)-Bip(2-Ipr)
HA-(CH2)3-DBip(2-Ipr)-DBip(2-Ipr)
HA-(CH2)3-Bip(2-Me)-Bip(2-CN)
HA-(CH2)3-Bip-Bip(2-CN)
HA-(CH2)3-Bip(2-Et)-Bip(2-CN) HA-(CH2)3-Bip(2-Ipr)-Biρ(2-CN)
HA-(CH2)3-Bip(2-CN)-Bip(2-Me)
HA-(CH2)3-Bip(2-CN)-Bip
HA-(CH2)3-Bip(2-CN)-Bip(2-Et)
HA-(CH2)3-Bip(2-CN)-Bip(2-Ipr) HA-(CH2)3-Bip(2-CJN)-Biρ(2-CN)
HA-(CH2)2-F-(CH2)2-Bip(2-Et)-DBip(2-Et)
HA-(CH2)2-F-(CH2)2-Bip(2-Et)-DBip(2-Me)
HA-(CH2)5-Bip(2-Me)-DBiρ
HA-(CH2)3-Bip(2-Me)-DBip-R HA-(CH2)3-DBip(2-Me)-DBip
HA-(CH2)5-Bip(2-Me)-DBip(2-Me)
HA-(CH2)5-DBip(2-Me)-Bip(2-Me)
HA-(CH2)4-D(Bip)-Bip(2-Et)
HA-(CH2)5-D(Bip)-Bip(2-Et) HA-(CH2)4-Bip(2-Me)-DBip(2-Me)
HA-(CH2)5-Bip(2-Me)-DBip(2-Me)
HA-(CH2)3-(N(Me))-DBip-Bip(2-Et)
HA-(CH2)4-DBip(2-Me)-Bip(2-Et)
HA-(CH2)5-DBip(2-Me)-Bip(2-Et) HA-(CH2)3-(N(Me))-DBip(2-Me)-Bip(2-Et)
HA-(CH2)4-Bip(2-Me)-DBip
HA-(CH2)5-Bip(2-Me)-DBip
HA-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)
HA-(N(Me))-(CH2)3-DBip(2-Me)-Bip(2-Et) HA-(N(Me))-(CH2)3-DBip-Bip(2-Et) HA-(N(Me))-(CH2)3-Bip(2-Et)-Bip(2-Me) HA-(N(Me))-(CH2)3-Bip(2-Me)-DBip HAE-(CH2)2-F-(CH2)2-Bip(2-Et)-DBip(2-Et) HAE-(CH2)2-F-(CH2)2-Bip(2-Et)-DBip(2-Me)
HAib-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)
6. The isolated polypeptide of claim 1 wherein the isolated polypeptide is a compound selected from HA-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-Aib-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
Ha-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 H-(N(Me))Aib-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-NH2
H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-NH2 H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH2
H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4- (2'-Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me»-
4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH-(CH2)6-CH3 H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH-(CH2)10-CH3 H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)i0-CH3
CH3-(CH2)6-NH-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 CH3-(CH2)6-NH-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NΗ-(CH2)6-CH3
CH3-(CH2)1o-NH-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
HA-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-Aib-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
Ha-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 H-(N(Me))A-(N(Me))-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-(N(Me))-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-NH2
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr- AIa-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH2
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH2 Des-amino-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-
(2'-Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)- 3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH-(CH2)10-CH3 H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)i0-CH3
CH3-(CH2)6-NH-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)io-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
HA-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-Aib-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-a-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NΗ2
H-(N(Me))A-(CH2)4-Biρ(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 H-(N(Me))A-(N(Me))-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-(N(Me))-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-NH2
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr- AIa-NH2
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH2
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH2 Des-amino-H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-
(2'-Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)- 3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-NH-(CH2)10-CH3 H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)10-CH3
CH3-(CH2)6-NH-H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)io-NH-H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)10-NH-H-N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
HAE-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-Aib-E-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
HaE-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))AE-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 H-(N(Me))AE-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-E-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-
NH2
H-(N(Me))AE^(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-NH2 H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-NH2
H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)io-CH3
H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)10-CH3 CH3-(CH2)6-NH-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)6-NH-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)io-NH-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
HAEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-Aib-EG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 HaEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))AEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))AEG-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-EG-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-
NH2 H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-NH2
H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-NH2
H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 Des-amino-H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)io-CH3 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-NH-(CH2)io-CH3
CH3-(CH2)6-NH-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)6-NH-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)io-NH-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)1o-NH-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 HAEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-Aib-EGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
HaEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))AEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
H-(N(Me))AEGT-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala- NH2
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-
NH2
H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-NH2 H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-NH2
H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH2
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'- Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2
Des-amino-H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH2 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-NH-(CH2)io-CH3
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-NH-(CH2)io-CH3
CH3-(CH2)6-NH-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)6-NH-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
CH3-(CH2)io-NH-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3 CH3-(CH2)io-NH-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-NH-(CH2)6-CH3
HA-(CH2)3-Bip(2-Me)-Bip(2-Me)-NH2 H-Aib-(CH2)3-Bip(2-Me)-Bip(2-Me)-NH2 Ha-(CH2)3-Bip(2-Me)-Bip(2-Me)-NH2 H-(N(Me))A-(CH2)3-Bip(2-Me)-Bip(2-Me)-NH2
H-(N(Me))A-(N(Me))-(CH2)3-Bip(2-Me)-Bip(2-Me)-NH2 H-(N(Me))Aib-(N(Me))-(CH2)3-Bip(2-Me)-Bip(2-Me)-NH2 H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Biρ(2-Me)-Biρ(2-Me)-NH2 H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-Bip(2-Me)-NH2 H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-NH2
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-NH2 Des-amino-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)- NH2
Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2- Me)-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Biρ(2-Me)-(N(Me))-Bip(2-Me)-NH- (CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-NH- (CH2)6-CH3 H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-NH-
(CH2)10-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-NH-
(CH2)I0-CH3 CH3-(CH2)6-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-NH-(CH2)6-CH3
CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-NH-(CH2)6-CH3
CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))- Bip(2-Me)-NH-(CH2)6-CH3
CH3-(CH2)10-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-NH-(CH2)6-CH3
HA-(CH2)3-Bip(2-Et)-Bip(2-Me)-NH2
H-Aib-(CH2)3-Bip(2-Et)-Bip(2-Me)-NH2 Ha-(CH2)3-Bip(2-Et)-Bip(2-Me)-NH2
H-(N(Me))A-(CH2)3-Bip(2-Et)-Bip(2-Me)-NH2
H-(N(Me))A-(N(Me))-(CH2)3-Bip(2-Et)-Bip(2-Me)-NH2
H-(N(Me))Aib-(N(Me))-(CH2)3-Bip(2-Et)-Bip(2-Me)-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)-NH2 H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-NH2
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-NH2
Des-amino-H-(N(Me))A-(N(Me))-(CΗ?)r(N(Me))-Bi'p(2-F,t)-(N(Me))-Bip(2-Me)-
NH2 Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-
Me)-NH2
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-NH-(CH2)6-
CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-NH- (CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-NH-(CH2)io-
CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-NH-
(CH2)I0-CH3 CH3-(CH2)6-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-
Me)-NH-(CH2)6-CH3
CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-
Bip(2-Me)-NH-(CH2)6-CH3 CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-
Me)-NΗ-(CH2)6-CH3
CH3-(CH2)10-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-
Bip(2-Me)-NH-(CH2)6-CH3
HA-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-Aib-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
Ha-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
Η-(N(Me))A-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))Aib-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)- 3-Pyr-Ala-OH
H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-OH .
Des-amino-H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-
(2'-Me-Ph)-3-Pyr-Ala-OH Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-COO-(CH2)io-CH3
H-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)io-CH3 CH3-(CH2)6-NH-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)6-NH-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 CH3-(CH2)io-NH-(N(Me))A-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)io-NH-(N(Me))Aib-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
HA-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-Aib-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
Ha-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(N(Me))-(CH2)3-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-Biρ(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)- 3-Pyr-Ala-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-
(2'-Me-Ph)-3-Pyr-Ala-OH Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-COO-(CH2)10-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2),o-CH3 CH3-(CH2)6-NH-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Biρ(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)jo-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
HA-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-Aib-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
Ha-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(N(Me))-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))Aib-(N(Me))-(CH2)4-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)- 3-Pyr-Ala-OH
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-
(2'-Me-Ph)-3-Pyr-Ala-OH Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-Ph)-
3-Pyr-Ala-COO-(CH2)io-CH3
H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)jo-CH3 CH3-(CH2)6-NH-H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)io-NH-H-N(Me))Aib-(N(Me))-(CH2)4-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
HAE-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-Aib-E-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
HaE-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AE-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AE-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)^3-Pyr-Ala-OH
H-(N(Me))Aib-E-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-OH
H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-OH
H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-
4-(2'-Me-Ph)-3-Pyr-Ala-OH Des-amino-H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me- Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)10-CH3 H-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)10-CH3 CH3-(CH2)6-NH-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)6-NH-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 CH3-(CH2)io-NH-(N(Me))AE-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))Aib-E-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
HAEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-Aib-EG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
HaEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AEG-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AEG-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))Aib-EG-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala- OH
H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Biρ(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-
AIa-OH
H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-OH H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-OH
H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)10-CH3 H-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-COO-(CH2)10-CH3
CH3-(CH2)6-NH-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 CH3-(CH2)6-NH-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))AEG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))Aib-EG-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
HAEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-Aib-EGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
HaEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AEGT-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-OH H-(N(Me))AEGT-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-
OH
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-Pyr-Ala-
OH
H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3- Pyr-Ala-OH
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-4-(2'-Me-Ph)-3-
Pyr-Ala-OH
H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-OH H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-OH
Des-amino-H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-OH
H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3 H-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-Me-
Ph)-3-Pyr-Ala-COO-(CH2)io-CH3
H-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-(N(Me))-4-(2'-
Me-Ph)-3-Pyr-Ala-COO-(CH2)10-CH3 CH3-(CH2)6-NH-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)6-NH-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))AEGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)- (N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
CH3-(CH2)10-NH-(N(Me))Aib-EGT-(N(Me))-(CH2)2-(N(Me))-Bip(2'-Et-4'-OMe)-
(N(Me))-4-(2'-Me-Ph)-3-Pyr-Ala-COO-(CH2)6-CH3
HA-(CH2)3-Bip(2-Me)-Biρ(2-Me)-OH
H-Aib-(CH2)3-Bip(2-Me)-Bip(2-Me)-OH Ha-(CH2)3-Bip(2-Me)-Bip(2-Me)-OH
H-(N(Me))A-(CH2)3-Bip(2-Me)-Bip(2-Me)-OH
H-(N(Me))A-(N(Me))-(CH2)3-Bip(2-Me)-Bip(2-Me)-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-Bip(2-Me)-Bip(2-Me)-OH
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Biρ(2-Me)-Bip(2-Me)-OH H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-Bip(2-Me)-OH
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-OH
Des-amino-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-
OH Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-
Me)-OH
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-COO-
(CH2)6-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-COO- (CHz)6-CH3
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-COO-
(CH2)10-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-Bip(2-Me)-COO-
(CHz)1O-CH3 CH3-(CH2)6-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-COO-(CH2)6-CH3
CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-COO-(CH2)6-CH3 CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-COO-(CH2)6-CH3
CH3-(CH2)10-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Me)-(N(Me))-
Bip(2-Me)-COO-(CH2)6-CH3
HA-(CH2)3-Bip(2-Et)-Bip(2-Me)-OH H-Aib-(CH2)3-Bip(2-Et)-Bip(2-Me)-OH
Ha-(CH2)3-Bip(2-Et)-Bip(2-Me)-OH
H-(N(Me))A-(CH2)3-Bip(2-Et)-Bip(2-Me)-OH
H-(N(Me))A-(N(Me))-(CH2)3-Bip(2-Et)-Bip(2-Me)-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-Bip(2-Et)-Bip(2-Me)-OH H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-Bip(2-Me)-OH
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-OH
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-OH
Des-amino-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)- OH
Des-amino-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Biρ(2-Et)-(N(Me))-Bip(2-
Me)-OH
H-(N(Me))A-(N(Mc))-(CH2)3-(N(Mc))-Bip(2-Et)-(N(Mc))-Bip(2-Mc)-COO-
(CHa)6-CH3 H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-COO-
(CH2)6-CH3
H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-COO-
(CHa)10-CH3
H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-Me)-COO- (CH2)IO-CH3
CH3-(CH2)6-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-
Me)-COO-(CH2)6-CH3
CH3-(CH2)6-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-
Bip(2-Me)-COO-(CH2)6-CH3 CH3-(CH2)10-NH-H-(N(Me))A-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-Bip(2-
Me)-COO-(CH2)6-CH3
CH3-(CH2)10-NH-H-(N(Me))Aib-(N(Me))-(CH2)3-(N(Me))-Bip(2-Et)-(N(Me))-
Bip(2-Me)-COO-(CH2)6-CH3 HA-(CH2)3-DVSSYLEGQAAKEFIKELEKLL
HAib-(CH2)3-DVSSYLEGQAAKEFIKELEKLL
HAibEGTFTSDVSSYLEGQ-(CH2)2-KELEKLL
HAibEGTFTSDVSSYLEGQ-(CH2)3-KELEKLL
HAibEGTFTSDVSSYLE-(CH2)2-FIKELEKLL HAibEGT-(α-Me)Phe(2-F)-TSDVSSYLE-(CH2)2-FIKELEKLL
HAib-(CH2)3-VSSYLE-(CH2)2-FIKELEKLL
HAib-(CH2)3-VSSYLE-(CH2)3-FIKELEKLL
HAib-(CH2)3-YLE-(CH2)3-FIKELEKLL
HAib-(CH2)4-YLE-(CH2)3-FIKELEKLL HAib-(CH2)4-YL-(CH2)3-FIKELEKLL
HAib-(CH2)4-Y-(CH2)3-FIKELEKLL
HAib-(CH2)4-FIKELEKLL
HAib-(CH2)5-FIKELEKLL
HAib-(CH2)6-FIKELEKLL HAib-(CH2)8-FIKELEKLL
HAib-(CH2)3-VSSYLEGQ-(CH2)3-KELEKLL
HAib-(CH2)3-VSSYLEG-(CH2)3-KELEKLL
HAib-(CH2)3-VSSYLE-(CH2)4-KELEKLL
HAib-(CH2)3-SSYLE-(CH2)4-KELEKLL HAib-(CH2)3-SYLE-(CH2)4-KELEKLL
HAib-(CH2)3-YLE-(CH2)4-KELEKLL
HAib-(CH2)3-YL-(CH2)4-KELEKLL
HAib-(CH2)3-Y-(CH2)4-KELEKLL
HAib-(CH2)5-KELEKLL HAib-(CH2)6-KELEKLL
HAib-(CH2)8-KELEKLL
7. A pharmaceutical composition comprising compounds as claimed in claims 1-6 prepared according to the processes described herein and a suitable pharmaceutically acceptable carrier(s).
8. The compounds or their pharmaceutical compositions as claimed in claims 1-7, which possess the ability to mimic the biological activity of GLP-I, more preferably mimic the GLP-IR agonist activity.
9. The compounds or their pharmaceutical compositions as claimed in any of the claims 1-7, useful for the treatment or prevention of diseases wherein GLP-IR peptide plays a patho-physiological function.
10. A method of preventing or treating diseases caused by hyperlipidaemia, hypercholesteremia, hyperglycemia, hyperinsulinemia, elevated blood levels of free fatty acids or glycerol, hypertriglyceridemia, wound healing, obesity, impaired glucose tolerance, leptin resistance, insulin resistance, diabetic complications, such as nephropathy, retinopathy, neuropathy and cataracts, comprising administering an effective, non-toxic amount of compound of formula (I) as defined in any preceding claims to a patient in need thereof.
11. The method according to any preceding claims, wherein the disease is type 2 diabetes, impaired glucose tolerance, dyslipidaemia, hypertension, obesity, atherosclerosis, hyperlipidaemia, coronary artery disease, cardiovascular disorders and other diseases wherein insulin resistance is the underlying pathophysiological mechanism.
12. A medicine for treating/reducing any of the disease conditions described in any preceding claims which comprises administering a compound of formula (I), as defined in claims 1-7 and a pharmaceutically acceptable carrier, diluent, excipients or solvate to a patient in need thereof.
13. A medicine for treating/reducing any of the disease conditions described in any preceding claims which comprises administering a compound of formula (I), as defined in claims 1-7 in combination with a suitable DPP IV inhibitor, to a patient in need thereof.
14. Use of compounds of formula (I), alone or in combination with suitable DPP IV inhibitors, their pharmaceutical compositions and medicines containing them as defined in any previous claims as a medicament suitable for the treatment of diseases mentioned in any of the aforesaid claims.
PCT/IN2006/000154 2005-05-05 2006-05-04 Novel compounds as glp-i agonists WO2007017892A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2008509578A JP2008540402A (en) 2005-05-05 2006-05-04 Novel compounds as GLP-1 agonists
AU2006277557A AU2006277557A1 (en) 2005-05-05 2006-05-04 Novel compounds as GPL-I agonists
EA200702419A EA200702419A1 (en) 2005-05-05 2006-05-04 NEW CONNECTIONS AS GLP-1 AGONISTS
AP2007004227A AP2007004227A0 (en) 2005-05-05 2006-05-04 Novel compounds as GLP-1 agonists
CA002606894A CA2606894A1 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists
MX2007013655A MX2007013655A (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists.
BRPI0612471A BRPI0612471A2 (en) 2005-05-05 2006-05-04 new compounds as glp-1 agonists
EP06809915A EP1891106A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists
IL187105A IL187105A0 (en) 2005-05-05 2007-11-01 Novel compunds as glp-i agonists
NO20075618A NO20075618L (en) 2005-05-05 2007-11-06 Novel compounds as GLP-1 Agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN558/MUM/2005 2005-05-05
IN558MU2005 2005-05-05
IN645/MUM/2005 2005-05-31
IN645MU2005 2005-05-31

Publications (2)

Publication Number Publication Date
WO2007017892A2 true WO2007017892A2 (en) 2007-02-15
WO2007017892A3 WO2007017892A3 (en) 2007-09-20

Family

ID=37727716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000154 WO2007017892A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists

Country Status (12)

Country Link
EP (1) EP1891106A2 (en)
JP (1) JP2008540402A (en)
KR (1) KR20080021636A (en)
AP (1) AP2007004227A0 (en)
AU (1) AU2006277557A1 (en)
BR (1) BRPI0612471A2 (en)
CA (1) CA2606894A1 (en)
EA (1) EA200702419A1 (en)
IL (1) IL187105A0 (en)
MX (1) MX2007013655A (en)
NO (1) NO20075618L (en)
WO (1) WO2007017892A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
WO2009125424A2 (en) * 2007-12-11 2009-10-15 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
JP2011506376A (en) * 2007-12-11 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー Insulin secretory peptide synthesis using combined solid and solution phase techniques
WO2010125079A3 (en) * 2009-05-01 2011-04-07 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
US7960349B2 (en) 2006-05-26 2011-06-14 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
WO2011153965A1 (en) 2010-06-11 2011-12-15 北京精益泰翔技术发展有限公司 Fusion protein of exendin-4 and its analog, preparation method and use thereof
WO2014127120A1 (en) 2013-02-15 2014-08-21 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576023A (en) * 2006-10-03 2012-06-29 Cadila Healthcare Ltd Antidiabetic compounds comprising a fragment of a glucagon peptide and derivatives thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2002028438A1 (en) * 2000-10-05 2002-04-11 King's College London Lipopeptides as absorption enhancers for bioactive compounds
WO2003011892A2 (en) * 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
WO2004094461A2 (en) * 2003-04-21 2004-11-04 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006014287A1 (en) * 2004-07-02 2006-02-09 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006024275A2 (en) * 2004-09-03 2006-03-09 Philipps-Universität Marburg Glp-1 and exendin related invention

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2002028438A1 (en) * 2000-10-05 2002-04-11 King's College London Lipopeptides as absorption enhancers for bioactive compounds
WO2003011892A2 (en) * 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
WO2004094461A2 (en) * 2003-04-21 2004-11-04 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006014287A1 (en) * 2004-07-02 2006-02-09 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2006024275A2 (en) * 2004-09-03 2006-03-09 Philipps-Universität Marburg Glp-1 and exendin related invention

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AL-SABAH SULEIMAN ET AL: "A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 140, no. 2, September 2003 (2003-09), pages 339-346, XP002437826 ISSN: 0007-1188 *
CHAHRZAD MONTROSE-RAFIZADEH ET AL: "High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 21201-21206, XP002247450 ISSN: 0021-9258 *
DOYLE MAIRE E ET AL: "The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity." REGULATORY PEPTIDES, vol. 114, no. 2-3, 15 July 2003 (2003-07-15), pages 153-158, XP002441636 ISSN: 0167-0115 *
GREEN B D ET AL: "STRUCTURALLY MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) AS FUTURE ANTIDIABETIC AGENTS" CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 10, no. 29, 2004, pages 3651-3662, XP009068381 ISSN: 1381-6128 *
HINKE SIMON A ET AL: "In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide" LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 75, no. 15, 27 August 2004 (2004-08-27), pages 1857-1870, XP002387302 ISSN: 0024-3205 *
RUNGE S ET AL: "Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity." BRITISH JOURNAL OF PHARMACOLOGY, vol. 138, no. 5, March 2003 (2003-03), pages 787-794, XP002427759 ISSN: 0007-1188 *
XIAO Q ET AL: "Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 40, no. 9, 6 March 2001 (2001-03-06), pages 2860-2869, XP002277645 ISSN: 0006-2960 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7960349B2 (en) 2006-05-26 2011-06-14 Bristol-Myers Squibb Company N-terminally modified GLP-1 receptor modulators
WO2009125424A2 (en) * 2007-12-11 2009-10-15 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
WO2009125424A3 (en) * 2007-12-11 2009-12-23 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
JP2011506428A (en) * 2007-12-11 2011-03-03 カディラ ヘルスケア リミティド Peptidomimetics having glucagon antagonist activity and GLP-1 agonist activity
JP2011506376A (en) * 2007-12-11 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー Insulin secretory peptide synthesis using combined solid and solution phase techniques
US8883963B2 (en) 2007-12-11 2014-11-11 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities
EA018000B1 (en) * 2007-12-11 2013-04-30 Кадила Хелзкэр Лимитед Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
JP2012525348A (en) * 2009-05-01 2012-10-22 エフ．ホフマン−ラ ロシュ アーゲー Insulin secretion-promoting peptide synthesis using solid phase and solution phase combination techniques
WO2010125079A3 (en) * 2009-05-01 2011-04-07 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
WO2011153965A1 (en) 2010-06-11 2011-12-15 北京精益泰翔技术发展有限公司 Fusion protein of exendin-4 and its analog, preparation method and use thereof
WO2014127120A1 (en) 2013-02-15 2014-08-21 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides
CN105101990A (en) * 2013-02-15 2015-11-25 梅约医学教育与研究基金会 Insulin secreting polypeptides
EP2956160A1 (en) * 2013-02-15 2015-12-23 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides
EP2956160A4 (en) * 2013-02-15 2016-08-03 Mayo Foundation Insulin secreting polypeptides
CN105101990B (en) * 2013-02-15 2017-12-22 梅约医学教育与研究基金会 insulin secretion polypeptide
US9938334B2 (en) 2013-02-15 2018-04-10 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides
US10336803B2 (en) 2013-02-15 2019-07-02 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides

Also Published As

Publication number Publication date
BRPI0612471A2 (en) 2016-09-06
KR20080021636A (en) 2008-03-07
JP2008540402A (en) 2008-11-20
EA200702419A1 (en) 2008-04-28
NO20075618L (en) 2008-01-30
WO2007017892A3 (en) 2007-09-20
IL187105A0 (en) 2008-02-09
CA2606894A1 (en) 2007-02-15
AU2006277557A1 (en) 2007-02-15
MX2007013655A (en) 2008-01-24
EP1891106A2 (en) 2008-02-27
AP2007004227A0 (en) 2007-12-31

Similar Documents

Publication Publication Date Title
AU2007323035B2 (en) Antidiabetic compounds
US8883963B2 (en) Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities
KR101205272B1 (en) Acylated glp-1 compounds
WO2014049610A2 (en) Peptides as gip, glp-1 and glucagon receptors triple-agonist
EP1891106A2 (en) Novel compounds as glp-i agonists
KR20070120112A (en) Extended glp-1 compounds
CN113366014A (en) Modified GIP peptide analogs
US20150141336A1 (en) Pancreatic Peptide Compounds and Use
BR112012029248B1 (en) GLP-1 ANALOG OF FORMULA I OR ITS COMPOSITION, GLP-1 ANALOG OF FORMULA VIII OR A PHARMACEUTICALLY ACCEPTABLE SALT OR THE COMPOSITION OF THE SAME, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
US20120264685A1 (en) Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
CN101223189A (en) Novel compounds as GLP-I agonists
CN115960258A (en) GLP-1/glucagon/Y 2 Receptor triple agonists and uses thereof
JP2012513981A (en) GLP-1 analog and use thereof

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/013655

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 187105

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008509578

Country of ref document: JP

Ref document number: 12007502447

Country of ref document: PH

Ref document number: 2606894

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006809915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006277557

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 07121830

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2006277557

Country of ref document: AU

Date of ref document: 20060504

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006277557

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077028300

Country of ref document: KR

Ref document number: 200702419

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 564030

Country of ref document: NZ

Ref document number: 1200702605

Country of ref document: VN

WWW Wipo information: withdrawn in national office

Ref document number: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06809915

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200680024277.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006809915

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0612471

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071105